

BMJ Paediatrics Open

BMJ Paediatrics Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Paediatrics Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjpaedsopen.bmj.com>).

If you have any questions on BMJ Paediatrics Open's open peer review process please email info.bmjpo@bmj.com

BMJ Paediatrics Open

A systematic review of early hearing detection and intervention (EHDI) programs for infants and young children in low and middle income countries in Asia

| | |
|-------------------------------|---|
| Journal: | <i>BMJ Paediatrics Open</i> |
| Manuscript ID | bmjpo-2022-001752 |
| Article Type: | Original research |
| Date Submitted by the Author: | 05-Nov-2022 |
| Complete List of Authors: | Joshi B, Deepashree; Sri Ramachandra Institute of Higher Education and Research (Deemed to be University), Sri Ramachandra Faculty of Audiology and Speech Language Pathology ; Sri Ramachandra Institute of Higher Education and Research (Deemed to be University), Sri Ramachandra Faculty of Audiology and Speech Language Pathology Ramkumar, Vidya; Sri Ramachandra Institute of Higher Education and Research (Deemed to be University), Sri Ramachandra Faculty of Audiology and Speech Language Pathology Nair, Lekha; National Institute of Speech and Hearing, Department of Audiology and Speech Language Pathology Kuper, Hannah; London School of Hygiene and Tropical Medicine Faculty of Public Health and Policy, Department of Population Health |
| Keywords: | Deafness, Neonatology, Health services research, Audiology |
| | |

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1 **TITLE:** A systematic review of early hearing detection and intervention (EHDI) programs for infants and
2 young children in low and middle income countries in Asia
3

4 **AUTHORS:**

5
6
7 Deepashree Joshi B¹ (First author), Vidya Ramkumar¹ (Corresponding author), Lekha S Nair², Hannah
8 Kuper³
9

10
11 **AFFILIATIONS:**

- 12
13
14 1. Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India – 600116
15 2. National Institute of Speech and Hearing, Trivandrum, Kerala, India - 695017
16 3. London School of Hygiene and Tropical Medicine, London, United Kingdom - WC1E 7HT
17

18 **Corresponding author:**

19
20
21 Dr. Vidya Ramkumar,
22 Associate professor,
23 Intermediate Fellow, DBT/Wellcome trust India Alliance,
24 Sri Ramachandra Faculty of Audiology and Speech, Language Pathology
25 Sri Ramachandra Institute of Higher Education and Research
26 Chennai, Tamil Nadu, India – 600116
27 Email id: vidya.ramkumar@sriramachandra.edu.in
28
29
30
31
32
33
34
35
36
37

38 **WORD COUNT:** 4484 (Excluding title page, abstract and references)
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

KEY WORDS

Hearing Screening

Hearing Impairment

Children

Early Hearing Detection and Intervention

Screening programs

Pediatrics

New born

Infants

Low Middle Income Countries

Asia

Confidential: For Review Only

Abbreviations

| | | |
|----|--------|--|
| 1 | | |
| 2 | EHDI | Early Hearing Detection and Intervention |
| 3 | | |
| 4 | LMIC | Low Middle Income Countries |
| 5 | | |
| 6 | HIC | High Income Countries |
| 7 | OAE | Oto Acoustic Emissions |
| 8 | | |
| 9 | AABR | Automated Auditory Brainstem Response |
| 10 | | |
| 11 | ABR | Auditory Brainstem Response |
| 12 | TEOAE | Transient Evoked Oto Acoustic Emissions |
| 13 | | |
| 14 | DPOAE | Distortion Product Oto Acoustic Emissions |
| 15 | | |
| 16 | PRISMA | Preferred Reporting Items for Systematic Reviews and Meta-Analyses |
| 17 | | |
| 18 | ICT | Information and Communication Technology |
| 19 | | |
| 20 | ASSR | Auditory Steady State Response |
| 21 | MeSH | Medical Subject Headings |
| 22 | | |
| 23 | WHO | World Health Organization |
| 24 | | |
| 25 | NHS | Newborn Hearing Screening |
| 26 | SNHL | Sensori Neural Hearing Loss |
| 27 | | |
| 28 | | |
| 29 | | |
| 30 | | |
| 31 | | |
| 32 | | |
| 33 | | |
| 34 | | |
| 35 | | |
| 36 | | |
| 37 | | |
| 38 | | |
| 39 | | |
| 40 | | |
| 41 | | |
| 42 | | |
| 43 | | |
| 44 | | |
| 45 | | |
| 46 | | |
| 47 | | |
| 48 | | |
| 49 | | |
| 50 | | |
| 51 | | |
| 52 | | |
| 53 | | |
| 54 | | |
| 55 | | |
| 56 | | |
| 57 | | |
| 58 | | |
| 59 | | |
| 60 | | |

ABSTRACT

Background: Early Hearing Detection and Intervention (EHDI) measures initiated in high income countries were attempted in LMICs. However, information regarding the models of EHDI, context specific adaptations made to strategies, and outcomes are not known. **Aim:** The aim of this systematic review was to identify the various models of EHDI used in the Asian LMICs in the published scientific literature, and to describe their efficacy and validity. **Method:** The studies were eligible if the program was from an Asian LMIC, implemented for children below 6 years of age and published between 2010 - 2021. Google Scholar, Pubmed, Web of Science, Scopus, EBSCOHost, and EBSCO-CINAHL were used to find articles. Data were extracted from each selected article, and the risk of bias was assessed. The search results were summarised using the PRISMA flow diagram. For primary outcomes, narrative synthesis was used, and forest plots were generated for secondary outcomes. **Results:** In all, 82 studies were included and these studies were divided into two categories: newborn and infant screening programmes and screening programmes for older children. Predominantly, a two-stage objective OAE(DP/TE) or AABR screening, followed by a detailed auditory brainstem response to confirm the hearing loss, was used in newborn and infant screening programmes. Audiologists were the most frequent screening personnel. Screening of older children was mostly done by otolaryngologists, school instructors, and nurses. They performed a single stage pure tone audiometry screening followed by a detailed examination. **Conclusion:** The screening tools and protocols used were similar to those used in high-income countries (HICs). However, no uniform protocols were followed within each country. Long term viability of EHDI programs was not known as there was limited information on impact outcomes such as cost-benefit.

INTRODUCTION

Currently, 34 million children below 15 years are estimated to have hearing loss, with a higher prevalence in low and middle income countries (2.4%) than in high income countries (0.5%) [1]. Early Hearing Detection and Intervention (EHDI) for children with hearing loss is critical to maximize linguistic competence and literacy development. EHDI is a concept that emanated in the United States in the 1990s and is intended as an, at-birth hearing screening of newborns prior to hospital discharge. Infants who do not pass the screening are recommended for diagnostic evaluation and, when confirmed to have hearing loss, are enrolled in early intervention programs. Subsequently, Joint Committee of Infant Hearing (JCIH) (2007) in the US, recommended that all infants should be screened for hearing by 1 month of age, diagnosed by 3 months and intervened by 6 months of age [2]. It is practiced as a mandatory universal screening in the entire country.

The concept was subsequently adopted in UK and practiced as universal screening since 2006. Slowly, several other high income countries (Australia, Canada to name a few) adopted this strategy. Alternative strategies for EHDI have been implemented in LMICs, due to financial, human resources, infrastructural challenges [3]. These include high-risk based screening [4], screening during immunization [5], community based hearing screening by health workers [6,7] and school entry level screening [8,9]. Several of these programs have also integrated tele-practice to either improve coverage of screening or to provide better diagnostic follow-up [10,11]. However, there remains a lack of clarity on the range of strategies implemented in LMICs, and which should be promoted.

The aim of this systematic review is to identify different models of EHDI that have been implemented in the context of Asian LMICs in the published scientific literature, and describe evidence of their efficacy and validity.

METHOD

The protocol for this systematic review was registered in PROSPERO (Reg No: CRD42021240341)

Inclusion criteria

All types of study designs were eligible for this review, including i) Cross-sectional ii) Cohort iii) Case-control iv) Randomized control trials v) Quasi-experimental and vi) field trials. Both qualitative and quantitative types of studies were included

The EHDI model is operationally defined for the purpose of this systematic review as programmes for identification and referral of young children with hearing loss. Studies that described EHDI programs related to triaging children suspected with hearing loss using methods such as objective or subjective screening, parental questionnaire based screening, implemented in the context of LMICs including hospital, community, school based or any other alternative approach were included.

1 Studies were eligible regardless of screening strategies (e.g. at birthing hospital/community/school), protocol
2 used (e.g. single stage/ two-stage), provider stakeholder (e.g. private/ public) involved, tools for screening
3 (e.g. checklist, OAE, AABR etc), or personnel involved in screening, diagnosis and intervention (e.g. nurse,
4 audiometrists, audiologist, ENT). We also included studies that explored evidence of validity (e.g.
5 sensitivity/specificity) and reported implementation barriers and facilitators to EHDI.
6
7

8
9 According to World Bank classification, Low and Middle-Income Countries (LMICs) in Asian continent
10 (South East Asia, Central Asia and Western Asia/Middle East) were considered as eligible for the review In
11 the LMICs, 6 years and below was considered as the age band for 'early' detection and intervention.
12 Therefore, this review included studies describing EHDI among neonates, infants and children below 6 years
13 of age. Studies were eligible if they had been published from 2010-2022.
14
15
16
17

18 19 **Exclusion criteria**

20
21 We excluded studies that described hearing screening programs for individuals older than 6 years of age, or
22 for other disabilities not including hearing. In addition, studies from high income countries, studies
23 published in languages other than English, and studies published before the year 2010 were excluded.
24
25
26
27

28 29 **Search strategy**

30
31 Since EHDI is an interdisciplinary program often implemented by ENT/ Pediatrics/ neonatology/ audiology/
32 nursing, databases that captured articles from multiple disciplines was preferred. The primary databases used
33 for the search includes; PUBMED, Scopus, Web of science, EBSCOHost, EBSCO-CINAHL (humanities
34 and social sciences), and Google scholar. Hand searching was conducted for the International Journal of
35 Audiology (2015 to 2022) and bibliographies of the selected papers based on the eligibility criteria. Grey
36 literature search included ProQuest Dissertations & Theses Global (Interdisciplinary) and first 500 searches
37 for articles/ reports in Google search. We excluded social media articles, newspaper articles, editorials,
38 website information.
39
40
41
42
43
44

45
46 A search strategy for each of the above mentioned databases was designed using 2Dsearch online tool[12] .
47 The search strategy included MeSH terms and Boolean operators (Appendix 1). A pilot search was
48 conducted in each database to identify the keywords. Synonyms of the keywords were then identified and
49 included in the search strategy.
50
51
52

53 54 **Screening for eligibility and quality**

55
56 Title screening was conducted as per the inclusion and exclusion criteria using database search. The Rayyan
57 software [13] was used to screen abstract and full texts. Screening was conducted by two reviewers (DJ,
58 VR) and any discrepancies were discussed between the reviewers and decisions were made. Joanna Briggs
59 Quality assessment tools specific to the research design was used to assess the quality of the articles.
60

1 PRISMA flowchart [14] was used to represent the search results.
2
3
4

5 **Data extraction and synthesis:** 6

7
8 A Google sheet was used for data extraction, which was undertaken by two authors (DJ and LN) and was
9 verified by another author (VR).
10

11
12 Narrative synthesis of available data was conducted using textual approach to describe strategies adopted for
13 EHDI including screening methods, service delivery points, use of information and communications
14 technology (ICT), the target age groups of such programs, personnel involved in delivery of the program and
15 reported barriers and facilitators of the program. JBI tool for critical appraisal [15] was used for quality
16 assessment. The Synthesis Without Meta-analysis (SWiM) guideline was used for analysis of secondary
17 outcomes [16]. If a country had at least three studies that reported data on children with confirmed hearing
18 loss, then that country was included for estimation of prevalence per 1000 using forest plots.
19
20
21
22
23
24

25 The primary outcomes of interest were i) validity and efficacy of the screening
26 programmes. We developed a checklist (Figure 2A & 2B) to assess the validity and efficacy using three
27 criteria each. The items in the validity checklist included; i) the use of a *validated screening tool*, ii) the use
28 of a *validated diagnostic tool*, whether the screening programme reported was in the iii) *design phase* (e.g.
29 pilot/feasibility/validity/only reported coverage rate or referral rate or follow up
30 rate) or *implementation phase* (e.g. scale programme). The efficacy was assessed if the study reported the
31 i) evidence of early identification ii) evidence of early intervention ii) inclusion of an economic analysis.
32
33
34
35
36
37

38 The secondary outcome of interest was to estimate the incidence & prevalence outcomes of EHDI programs
39 in the LMIC Asian countries. For secondary outcomes analysis, in screening programs for newborns and
40 infants, the prevalence of hearing loss in infants reported in each country was analyzed using the SWIM
41 guidelines. Using a random effect model, Forest plots (Figure 3A-E) were constructed for each country
42 based on two criteria: if more than five studies in a country reported prevalence outcomes, and if the number
43 of children screened was more than one thousand.
44
45
46
47
48

49 **RESULTS** 50

51 Our electronic search yielded 1312 citations. Based on the inclusion/exclusion criteria and multiple levels of
52 screening by the two reviewers independently, a total of 82 studies qualified for the current review. The article
53 selection process is presented in the PRISMA flow chart (Figure 1). Sixty five (79%), reported on newborn
54 hearing screening, and only seventeen studies (21%) reported hearing screening among older children.
55 Predominantly studies were conducted in India (n=27) followed by Turkey (n=13), Iran (n=13), China (n=15),
56 Thailand (n=6), Malaysia (n=3), Nepal (n=1), Bangladesh (n=1), Iraq (n=1), Jordan (n=1), Tajikistan (n=1).
57
58
59
60

1 These studies included 75 cross sectional studies and 7 cohort studies. Results of quality appraisal using
2 appropriate JBI tool is provided in supplementary file 1.
3
4

5 ***Insert Figure 1: PRISMA flowchart representing the selection of article at each stage***
6
7

8 The screening programs identified in this review were grouped based on the age group of the children: 1)
9 screening programs for newborns and infants (0-3 years of age); screening programs for older children even
10 beyond 6 years of age.
11
12

13
14 Hearing screening programs for newborns and infants (below 2 years) included 65 studies. Most studies (49)
15 reported single-hospital programmes, whereas others (16 studies) reported multiple-center programmes. Of
16 these studies, 55 were undertaken in the private sector and 10 in the public sector. There were 17 studies of
17 hearing screening programmes for older children aged 3 to 17. Fifteen of these studies were school-based
18 hearing screenings, while two were community-based. Of these studies, 9 were undertaken in the private
19 sector and 8 in the public sector. Table 1A to E represent the summary of included studies describing hearing
20 screening programs for newborns and infants in each country.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1A: Hearing screening programs for newborns and infants in India

| Author and Year | Citation | Country | Years of program | Population screened | Number screened | Screening protocol | Screening test used | Screening personnel | Diagnostic test |
|-----------------------------|----------|---------|------------------|----------------------------|---|---|--|---|-----------------------------|
| Biswas et al., 2012 | [17] | India | 2 years | newborns | 490 | 1 stage | DPOAE | Not mentioned | Not mentioned |
| Paul et al., 2011 | [18] | India | 7 years | newborns | 10165 | 2 stage | OAE + OAE (not mentioned DP/TE) | Person with basic knowledge in computer with training on NHS. | Diagnostic ABR |
| Mishra et al., 2013 | [19] | India | 3 years | 0-2 years | 1101 | <6 months of age- 5 stage; 6m to 1yr-4 stage ; 1 yr to 2 yrs -3 stage | DPOAE | Not mentioned | Diagnostic ABR |
| Ramesh et al., 2012 | [20] | India | 2 years | newborns | 425 | 1 stage | Calibrated noise maker based BOA | Trained health workers (30 hours of training) | Diagnostic ABR, OAE & BOA |
| Rai & Takur et al., 2013 | [21] | India | 1 year | newborns | 500 | 3 stage | TEOAE +TEOAE +TEOAE | ENT | Diagnostic ABR |
| Kumar et al., 2015 | [22] | India | 1 year 8 months | High risk < 2 years of age | 500 | 2 stage | TEOAE+AABR | Audiologist | Not mentioned |
| Gupta et al., 2015* | [23] | India | 1 year | newborns | 2265 | 2 stage | AABR + AABR | Single specialist staff | Not mentioned |
| Vignesh et al., 2015 * | [24] | India | 1.5 years | newborns | 1405 | 2 stage | TEOAE+AABR | Not mentioned | Diagnostic ABR |
| Vishwakarma et al., 2015 | [25] | India | 1 year 8 months | newborns | Wellbabies : 2000 high risk :1020 | 3 stage | TEOAE+TEOAE + AABR | Nurse, Resident doctor/ certified audiologist | Diagnostic ABR |
| Paul et al., 2016 | [26] | India | 11 years | newborns | Wellbabies : 84774 High risk: 16,914 | 2 stage | OAE+ OAE (Not mentioned DP/TE) | Person with basic training in hearing screening | Diagnostic ABR |
| Sharma et al., 2018 | [27] | India | 3 years | newborns | 2534 | 2 stage | DPOAE | Not mentioned | Diagnostic ABR |
| Kumar et al., 2016* | [28] | India | 2 years | newborns | 1537 | 2 stage | TEOAE+TEOAE + AABR | Not mentioned | Not mentioned |
| Sachdeva & Sao et al., 2017 | [29] | India | 10 months | newborns | 2254 | 2 stage | (HRR + BOA + DPOAE) + DPOAE | Not mentioned | Confirmatory Diagnostic ABR |
| Kumar et al., 2017 | [30] | India | No info | newborns | 600 | 2 stage | TEOAE+DPOAE | Not mentioned | Not mentioned |
| Swain et al., 2017 | [31] | India | 1.5 years | newborns | 410 | 2 stage | DPOAE + DPOAE | Not mentioned | Diagnostic ABR |
| Bhat et al., 2018 | [32] | India | 1 year | High risk newborns | 195 | 1 stage | TEOAE | Not mentioned | Diagnostic ABR |
| Bishnoi et al., 2018 | [33] | India | No info | newborns | 2000 | 2 stage | (OAE & TYMP) + OAE (not mentioned DP/TE) | Not mentioned | Diagnostic ABR |
| Parab et al., 2018 * | [34] | India | 3 years | newborns | 8192 | 2 stage | TEOAE + TEOAE | Audiologist | Diagnostic ABR |
| Jacob et al., 2020 | [35] | India | 2 years | newborns | 773 | 2 stage | TEOAE +TEOAE | Not mentioned | Diagnostic ABR |

| | | | | | | | | | |
|--------------------|------|-------|---------|----------|-------|---------|-------------------------------|---------------|----------------|
| Nishad et al.,2020 | [36] | India | 1 year | newborns | 1000 | 2 stage | OAE+OAE (not mentioned DP/TE) | Not mentioned | Diagnostic ABR |
| Sija et al., 2022 | [37] | India | 4 years | Newborns | 16265 | 2 stage | DPOAE +DPOAE | Trained nurse | Diagnostic ABR |

Table 1B: Hearing Screening programs for newborns and infants in China

| Author and Year | Citation | Country | Years of program | Population screened | Number screened | Screening protocol | Screening test used | Screening personnel | Diagnostic test |
|---------------------|----------|---------|------------------|---------------------|-----------------|-----------------------------|--|-----------------------------|--|
| Zhang et al., 2012* | [38] | China | 1.5 years | newborns | 10043 | 2 stage + genetic screening | TEOAE+ (TEOAE& AABR) | Nurse | Not mentioned |
| Tobe et al.,2013* | [39] | China | 2 years | newborns | Not mentioned | 2 stage | OAE+AABR (not mentioned DP/TE) | Trained personnel - no info | Not mentioned |
| Chen et al.,2012 | [40] | China | 2 years | newborns | 11568 | 2 stage | TEOAE | Audiologist | Diagnostic ABR, TFT, Impedance, ASSR at hospital |
| Shang et al.,2016 | [41] | China | 6 months | newborns | 1064 | 2 stage | 1st protocol: TEOAE + TEOAE 2nd protocol: (TEOAE & ABR screen) + TEOAE | Not mentioned | Diagnostic ABR |
| Wenjin et al., 2018 | [42] | China | 2 years | newborns | 19098 | 2 stage | Well babies : DPOAE + ABR screening High risk babies: (DPOAE & ABR screening) + (DPOAE & ABR screening) | Nurse | Otосcopy, Diagnostic ABR at 30dBHL, Tympanometry; DPOAEs |
| Wang et al., 2019 | [43] | China | 5 years | newborns | 55,977 | 2 stage | OAE+AABR (Non mentioned DP/TE) | Nurse | Comprehensive diagnostic audiometry around three months of age |
| Dai et al.,2019 | [44] | China | 1 year | newborns | 180469 | 2 stage + genetic screening | TEOAE + (TEOAE & AABR) | Not mentioned | Diagnostic ABR, ASSR, DPOAE, Immitance |
| Zeng et al., 2020 | [45] | China | 1 year | newborns | 4205 | 2 stage + genetic screening | OAE+AABR screening (Not mentioned DP/TE) | Not mentioned | No |
| Wen et al., 2020* | [46] | China | 2 years | newborns | 467980 | 2 stage | OAE + (OAE & AABR) (not mentioned DP/TE) | Not mentioned | Not mentioned |
| Guo et al., 2020 | [47] | China | 2 years 4 months | infants > 3 months | 2,87,430 | 2 stage + genetic | OAE +AABR (Non mentioned DP/TE) | Not mentioned | Diagnostic ABR |
| Guomei et al.,2022 | [48] | China | 9 months | Newborns | 2174 | 2 stage + genetic | OAE + OAE (Not mentioned DP/TE) | Not mentioned | Diagnostic ABR |

Table 1C: Hearing Screening Programs for newborns and infants in Southeast Asia

| Author and Year | Citation | Country | Years of program | Population screened | Number screened | Screening protocol | Screening test used | Screening personnel | Diagnostic test |
|-----------------------------|----------|------------|------------------|---------------------|-----------------|--------------------|--|--|-----------------------------------|
| Ahmad et al.,2011 | [49] | Malaysia | 5 years | newborns | 16000 | 3 stage | DPOAE +DPOAE + DPOAE | Technician, staff nurse, ward attendants | Diagnostic ABR |
| Wong et al.,2020 | [50] | Malaysia | 2 years | newborns | 28432 | 1 and 2 stage | 1 stage AABR 2 stage - DPOAE + AABR | Nurses | Diagnostic ABR |
| Tungvachira kul et al.,2011 | [51] | Thailand | 1 year 11 months | newborns | 4043 | 2 stage | OAE+ OAE (Not mentioned DP/TE) | Not mentioned | ASSR |
| Poonual et al.,2016 | [52] | Thailand | 1 year 7 months | newborns | 3120 | 2 stage | Automated TEOAE + Conventional TEOAE | Not mentioned | Diagnostic ABR |
| Poonual et al.,2017 | [53] | Thailand | Not mentioned | newborns | 3120 | 3 stage | COBRA HRR tool + TEOAE + AABR | Not mentioned | Not mentioned |
| Poonual et al., 2017b | [54] | Thailand | 1 year | newborns | 3120 | 2 stage | TEOAE+ AABR | Not mentioned | ABR at 3 and 8 months |
| Pitathawat hai et al.,2019 | [55] | Thailand | 1 year 7 months | newborns | 6140 | 2 stage | TEOAE+TEOAE | Nurses | Not mentioned |
| Ray et al.,2021 | [56] | Nepal | 2 years | newborns | 540 | 2 stage | OAE+OAE (Not mentioned DP/TE) | Not mentioned | Diagnostic OAE and Diagnostic ABR |
| Mazlan et al.,2022 | [57] | Malaysia | 10 years | newborns | 50633 | 2 stage | TEOAE +AABR | Trained nurses and medical technologists | Diagnostic ABR |
| Shameem et al., 2022 | [58] | Bangladesh | 2 years | High risk newborns | 426 | 2 stage | TEOAE + TEOAE | Not mentioned | Diagnostic ABR |
| Khaimook et al.,2022 | [59] | Thailand | 6 months | newborns | 1696 | 2 stage | TEOAE + TEOAE | Trained Nurse & audiologist | Diagnostic ABR + Tympanometry |

Table 1D: Hearing screening programs for newborns and infants in Turkey

| Author and Year | Citation | Country | Years of program | Population screened | Number screened | Screening protocol | Screening test used | Screening personnel | Diagnostic test |
|---------------------------|----------|---------|------------------|---------------------|---------------------------|--------------------|------------------------------|--|--|
| Tasci et al.,2010 | [60] | Turkey | 14 months | newborns | 16,975 | 3 steps | TEOAE+ TEOAE+ ABR | Audiology technician | Diagnostic ABR |
| Sennaroglu & Akmese, 2011 | [61] | Turkey | 1 year | newborns | 1840 | 2 stage | TEOAE | Audiologist or audiometrist | Diagnostic ABR; |
| Ulusoy et al.,2014 * | [62] | Turkey | 3 years | newborns | 11575 | 3 stage | TEOAE+ AABR | 2 audiometrists and 1 nurse | Diagnostic ABR, the level three center |
| Kemaloğlu et al., 2016 | [63] | Turkey | 10 years | newborns | 19436 (I/P) 2083 (O/P) | 3 stage | TEOAE+ TEOAE+ (TEOAE & AABR) | Audiology technicians and audiology students | Diagnostic ABR |
| Yorulmaz et al., 2017 | [64] | Turkey | 5 years | newborns | 13693 | 3 stage | TEOAE+TEOAE+AABR | Audiometrist | Diagnostic ABR, Tympanometry, Acoustic |

| | | | | | | | | | |
|-------------------------|------|--------|-----------|----------|---------------------------|---------|--|------------------|------------------|
| | | | | | | | | | reflexes, ASSR |
| Celik et al.,2016 | [65] | Turkey | 6 years | newborns | 142128 | 2 stage | TEOAE (twice same day)+ TEOAE | Not mentioned | Diagnostic ABR |
| Ozturk et al.,2017 | [66] | Turkey | 2 years | newborns | 7502 | 3 stage | Wellbabies: DPOAE+DPOAE+ABR screening Highrisk babies: Direct ABR | Audiologist | Diagnostic ABR |
| Hamdi, 2018 | [67] | Turkey | 2 years | newborns | 1808 | 3 stage | TEOAE+TEOAE+ABR screening | Nurses (Trained) | Diagnostic ABR |
| Yücel et al., 2019 | [68] | Turkey | 2 years | newborns | 786 syrian & 7230 turkish | 3 stage | (TEOAE & Tympanometry) + TEOAE + ABR | Not mentioned | Detailed testing |
| Arslan et al., 2013 | [69] | Turkey | 8 months | newborns | 2229 | 2 stage | TEOAE+TEOAE | Nurse | Diagnostic ABR |
| Çıkırıkçı et al., 2020* | [70] | Turkey | 1.5 years | newborns | 702 turkish 172 syrian | 2 stage | AABR + AABR | Not mentioned | Diagnostic ABR |

Table 1E: Hearing screening programs for newborns and infants in Iran

| Author and Year | Citation | Country | Years of program | Population screened | Number screened | Screening protocol | Screening test used | Screening personnel | Diagnostic test |
|-------------------------------|----------|---------|------------------|---------------------|-----------------|--------------------|--|--|-----------------------------------|
| Arjmandi et al., 2012 | [71] | Iran | 1 year | newborns | 1232 | 2 stage | TEOAE+TEOAE | Not mentioned | Diagnostic ABR |
| Islami et al.,2013 | [72] | Iran | 1.5 years | newborns | 7250 | 2 stage | TEOAE+TEOAE | Audiologists | Diagnostic ABR |
| Firoozbakht et al.,2014 | [73] | Iran | 8 years | newborns | 33,50,995 | 2 stage | TEOAE+AABR | audiologists, nurses, midwives and trained health technicians. | Comprehensive test |
| Zahed et al., 2014* | [74] | Iran | 8 years | newborns | 40930 | 2 stage | TEOAE+ABR | Audiologists | ABR/ASSR & immittance audiometry, |
| Farhat et al., 2014 | [75] | Iran | 2 years | newborns | 8987 | 2 stage | TEOAE+TEOAE | Not mentioned | ASSR |
| Haghshenas et al., 2014 | [76] | Iran | 2 years | newborns | 15,165 | 3 stage | OAE + OAE + (OAE & AABR) (Not mentioned DP/TE) | Audiologist | ABR screening |
| Baradaranfar et al., 2014 | [77] | Iran | 1 year | newborns | 514 | 2 stage | TEOAE+TEOAE | Not mentioned | Diagnostic ABR |
| Azizi et al., 2016 | [78] | Iran | 1.5 years | newborns | 3818 | 2 stage | TEOAE+TEOAE | not mentioned | ABR, |
| Tajik & Ahmadpour-Kacho, 2016 | [79] | Iran | 4 years | newborns | 3362 | 2 stage | TEOAE + (TEOAE & ABR) | Not mentioned | Not mentioned |
| Saki et al.,2017 | [80] | Iran | 3 years | newborns | 92,521 | 2 stage | 1st & 2nd:TEOAE + AABR | Audiologists | Diagnostic OAE and ABR |
| Rahimi et al.,2018 | [81] | Iran | 5 years | newborns | 4729 | 3 stage | TEOAE + TEOAE + AABR | Audiologist | Diagnostic ABR |

Table 2 : Hearing screening programs for older children

| Author and year | Citation | Country | Years of Program | Age of screening (years) | Number screened | Screening protocol | Screening test used | Pass/fail criteria | Screening personnel | Diagnostic test | Diagnostic person |
|---------------------------|----------|---------|------------------|--------------------------|-----------------|--------------------|---|---|--|--|---------------------------|
| Tuli et al.,2012 | [82] | India | 2 years | 5 to 16 | 111 | 1 stage | Case history, Audiological & ENT evaluation, Awareness &SIFTER | Not mentioned | Not mentioned | ENT & PTA & Diagnostic ABR | Audiologist |
| Chadha et al., 2013 | [83] | India | 3 years | 5 to 12 | 15718 | 1 stage | Otoscopy, Ten question screening index for disabilities" in English and Hindi | Positive history of hearing or speech defects, A positive finding on examination. | Proforma-parents, Otoscopy - otolaryngologists | Not mentioned | Not mentioned |
| Ramkumar et al.,2018 | [84] | India | 2 years | Birth to 5 years | 1335 | 2 stage | DPOAE +DPOAE | >SNR 3 dB | Trained Village Health Worker | Tele-Diagnostic ABR | Audiologist |
| Ramkumar et al.,2019 | [85] | India | 2 years | Birth to 5 years | 2815 | 2 stage | DPOAE + DPOAE | >SNR 3 dB | Trained Village Health Worker | Diagnostic ABR – in person and Tele-diagnostic ABR | Audiologist |
| Verma et al.,2022 | [86] | India | 6 months | 6 to 17 years | 597 | 1 stage | Tuning fork test | Not mentioned | Not mentioned | PTA and Tympanometry | Audiologist |
| Shekhar et al., 2020 | [87] | India | Not mentioned | 5 to 14 | 474 | 1 stage | PTA | Not mentioned | ENT specialist | ENT examination | ENT specialist |
| Lu et al.,2011 | [88] | China | 1 year | 3 to 6 | 21427 | 1 stage | PTA | 1, 2 and 4KHz > 20dB | Screening person with training (training program with certificate) | PTA (5 to 6 years) VRA or Play PTA (3 to 4 years) | Not mentioned |
| Chen et al.,2013 | [89] | China | 1 year 5 months | 3 to 6 | 28546 | 1 stage | TEOAE | >SNR 3 dB | School nurses & doctors 2 hours of training | Comprehensive test | Not mentioned Audiologist |
| Wu et al.,2014 | [90] | China | Not mentioned | 3 to 6 | 6288 | 1 stage | Software based new PTA | >30dBHL at 1,2,4KHz | Preschool teachers - minimally trained | Not mentioned | Not mentioned |
| Kam et al.,2014 | [91] | China | Not mentioned | 3 to 7 | 6231 | 1 stage | Automated PTA | >30dBHL at 1,2 and 4KHz | Automatic test - Nurses with 2 hours training as facilitator | Tympanometry, DPOAE & PTA (0.25 to 8KHz) | Not mentioned |
| Tokgöz-Yılmaz et al.,2013 | [92] | Turkey | 3 years | 3 to 5 | 239 | 1 stage | PTA | Not mentioned | Audiologist and SLP | ENT examination | ENT specialist |
| Kaplam et al.,2020 | [93] | Turkey | 1 year | 69 to 84 months | 23664 | 2 stage | PTA, Ten questionnaire | 500, 1000, 2000 and 4000Hz > 20dB Ten question - | Certified nurses, midwives, health officers or | ENT examination | ENT specialist |

| | | | | | | | | | | | | |
|----|-------------------------|------|------------|---------------|---------|------|---------------|---|--|--------------------------------------|---|---------------|
| | | | | | | | | Refer in 1 question | audiometrists, | | | |
| 1 | | | | | | | | | | | | |
| 2 | TarviEslami et al.,2017 | [94] | Iran | 1 year | 6 to 7 | 2237 | Not mentioned | PTA | Not mentioned | Not mentioned | PTA, Weber, Rinne test | Not mentioned |
| 3 | | | | | | | | | | | | |
| 4 | Jalali et al.,2020 | [95] | Iran | 4 months | 6 to 13 | 2019 | 1 stage | PTA | 0.5KHz to 4KHz >15dBHL | Not mentioned | ENT examination & comprehensive audiological examination | Not mentioned |
| 5 | | | | | | | | | | | | |
| 6 | | | | | | | | | | | | |
| 7 | | | | | | | | | | | | |
| 8 | | | | | | | | | | | | |
| 9 | | | | | | | | | | | | |
| 10 | | | | | | | | | | | | |
| 11 | | | | | | | | | | | | |
| 12 | Pilka et al.,2016 | [8] | Tajikistan | Not mentioned | 6 to 8 | 143 | 1 stage | Questionnaire, PTA using SZOK telemed model | PTA module (500 to 8KHz) >25dB at one frequency, | Medical doctors Other specialists | Detailed PTA | Audiologists |
| 13 | | | | | | | | | | | | |
| 14 | | | | | | | | | | | | |
| 15 | | | | | | | | | | | | |
| 16 | | | | | | | | | | | | |
| 17 | | | | | | | | | | | | |
| 18 | | | | | | | | | | | | |
| 19 | Alaqrabawi et al.,2016 | [96] | Jordan | 4 years | 5 to 15 | 1649 | 1 stage | PTA | 500Hz, 1KHz, 2KHz & 4KHz > 25dB | Not mentioned | Audiometry Otoscopy Tympanometry | Audiologists |
| 20 | | | | | | | | | | | | |
| 21 | | | | | | | | | | | | |
| 22 | | | | | | | | | | | | |
| 23 | Al-Obeidy et al.,2019 | [97] | Iraq | 1 year | 6 | 425 | 1 stage | HR Questionnaire | Not mentioned | Not mentioned | ENT examination, TFT (Weber, Rinne and Absolute bone conduction). HRR children: PTA | Not mentioned |
| 24 | | | | | | | | | | | | |
| 25 | | | | | | | | | | | | |
| 26 | | | | | | | | | | | | |
| 27 | | | | | | | | | | | | |
| 28 | | | | | | | | | | | | |
| 29 | | | | | | | | | | | | |
| 30 | | | | | | | | | | | | |
| 31 | | | | | | | | | | | | |
| 32 | | | | | | | | | | | | |
| 33 | | | | | | | | | | | | |
| 34 | | | | | | | | | | | | |
| 35 | | | | | | | | | | | | |
| 36 | | | | | | | | | | | | |
| 37 | | | | | | | | | | | | |
| 38 | | | | | | | | | | | | |
| 39 | | | | | | | | | | | | |
| 40 | | | | | | | | | | | | |
| 41 | | | | | | | | | | | | |
| 42 | | | | | | | | | | | | |
| 43 | | | | | | | | | | | | |
| 44 | | | | | | | | | | | | |
| 45 | | | | | | | | | | | | |
| 46 | | | | | | | | | | | | |
| 47 | | | | | | | | | | | | |
| 48 | | | | | | | | | | | | |
| 49 | | | | | | | | | | | | |
| 50 | | | | | | | | | | | | |
| 51 | | | | | | | | | | | | |
| 52 | | | | | | | | | | | | |
| 53 | | | | | | | | | | | | |
| 54 | | | | | | | | | | | | |
| 55 | | | | | | | | | | | | |
| 56 | | | | | | | | | | | | |
| 57 | | | | | | | | | | | | |
| 58 | | | | | | | | | | | | |
| 59 | | | | | | | | | | | | |
| 60 | | | | | | | | | | | | |

Abbreviations: PTA: Pure Tone Audiometry; ABR-Auditory Brainstem Response; DPOAE-Distortion Product OtoAcoustic Emissions; TEOAE-Transient Evoked Oto Acoustic Emissions; TFT-Tuning Fork Test; HRR-High Risk Register; SNR-Signal to Noise Ratio; SIFTER: Screening Identification For Targeting Educational Risk; Tympanometry

Screening protocol and tests:

Newborn and infant hearing screening:

Two-stage hearing screening protocols were employed most frequently for newborn and infant hearing screening (n=47), followed by three-stage protocols (n=13), and one-stage protocols (n=4). One study reported employing a 5-step hearing screening protocol.

Sixteen studies that reported a two-stage hearing screening protocol, employed otoacoustic emission (OAE) (TE/DP-OAE) or Automated Auditory Brainstem Response (AABR) as screening tests (individually or combined in either stage [22,24,32,42–47,50,53,57,73,74,79]. Other twenty five studies used only OAEs (DP/TE) [19,26,34–37,40,51,55,56,58,59,61,65,69,71,72,78] or AABR screening [23,70] for testing in both stages. Those studies that reported the use of AABR in the initial stage of screening either employed AABR solely for both stages [23] or a combination of AABR and OAE to screen only high-risk newborns [41,42]. Four studies from China used 2 stage screening coupled with genetic hearing screening [43–45,47,48]

When a three-stage protocol was used, generally the first two stages included OAE (DP/TE) screening followed by AABR/ABR screening [25,60,62–64,66,67,76,81] or included OAE(DP/TE) for all three stages [21,49]. Only one study reported combining tympanometry and TEOAE in the initial stage of its three-stage screening protocol [68]. Studies from Turkey (n=7) reported three-stage screening protocol [60,62–64,66–68].

Screening for older children

Fourteen studies for older children employed a single stage screening protocol [8,82,83,87,88,90–92,95–97] with three employing a two stage protocol [85,93]. Ten studies reported using subjective hearing screening tests, two studies used questionnaire or otoscopy for screening [83,97] and another three studies used TEOAE [84,85]. Pure tone audiometry was the most commonly used subjective test for screening older children [87,88,92,94–96]; Two studies reported the use of automated software based PTA [90,91]. Pure tone audiometry was combined with questionnaires [8,93] or otoscopy [83,97]. Only one study reported the use of TEOAE screening [89].

Pass/ refer criteria

In several programs for newborn and infant screening, screening results were based on data generated from the screening instrument automatically. The pass criteria for DP/TEOAE was between 3 and 6 dB SNR [18,21,25,30,32,37,40,42,47,49,55,59,63,65,78] and for AABR it varied between 30 dB nHL, 35 dB nHL and 40 dB nHL [41,42,62,64,76]. Predominantly, refer results in one ear was considered for follow-up screening.

1 For screening older children, the pass criteria for pure tone audiometry ranged from 15dB HL to 30dB HL.
2 All studies used the four frequencies 0.5KHz to 4KHz for pure tone testing. In questionnaire-based studies,
3 failing one item or a family history of hearing loss were the referral criteria [83,87].
4

6 **Screening personnel:**

8
9 Audiologists were the primary screening personnel in many newborn and infant programs
10 [22,25,34,39,40,61,66,72,74,76,80,81]; followed by nurses [25,37,42,43,49,50,55,57,59,62,67,69,73]. In five
11 studies, the training provided for nurses to perform hearing screening was also briefly mentioned
12 [55,57,67,69,73]. including some certifications [62]. Other than nurses, some studies reported audiometrists
13 [61,62,64] and audiologist technicians [60] as personnel involved in screening. Other non-specialists that were
14 engaged in hearing screening were technicians[49], ward attendants[49], trained health workers [20,73] social
15 workers [39]and midwives [18,26,73]. In a few programmes, otolaryngologists [21] performed the hearing
16 screening. 29 out of 59 studies did not provide any information regarding the screening individual.
17

18 Screening for older children was conducted by otorhinolaryngologists [8,83,87]audiologists [92], and
19 audiometrists [93]. Other non-specialists involved in the hearing screening included trained nurses/midwives
20 [40,91,93], trained village health workers or volunteers [84,85] and school teachers with training [90] .
21

22 Studies have reported a variety of training programmes. They included hearing screening certification [88,93];
23 2 hours of TEOAE training[40]; TEOAE training and tele-diagnostic testing facilitation [85]; and minimal
24 training/2 hours of training for facilitating automated PTA [90,91].
25

26 **Confirmation of hearing loss:**

27 Diagnostic Auditory Brainstem Response (ABR) was the only testing carried out to confirm the hearing loss
28 in studies in newborns and infants; [19,21,25,27,29,31,33,35–37,47,57,58]. Comprehensive test battery
29 including the diagnostic BERA, OAE, and tympanometry was mentioned only in eleven studies [42,64,73].
30 Four studies also reported the inclusion of the Auditory Steady State Response (ASSR) in the test battery
31 [64,74].
32

33 Two programs utilized solely ASSR [75] [51] and studies also used ABR screening at 30 dB nHL [42] or 35
34 dB nHL [76] for hearing loss diagnosis.
35

36 However, 11 of the 65 programs made no mention of the diagnostic confirmatory test used for confirmation
37 of hearing loss. More than half of the studies (n=37), reported that the diagnostic confirmatory test was
38 performed at the same hospital where screening was conducted. In another eighteen studies children were
39 referred to more specialist or tertiary care facilities for diagnostic confirmatory tests. The diagnostic site was
40 not mentioned or could not be inferred in 10 studies.
41

1 In studies reporting screening for older children, a test battery approach was used in 3 studies where they
2 included PTA with tympanometry and DPOAE [91] or PTA with otoscopy and tympanometry [96] or PTA
3 and detailed ABR [82]. Two studies reported the use of comprehensive test battery, but did not mention the
4 tests included [40].
5
6

7
8 Puretone audiometry (PTA) was frequently included in the diagnostic test battery [86,91,96]. While PTA was
9 used as the only diagnostic test in three studies [8]. Apart from these studies, ENT examination was included
10 in five studies [87,92,93,95,97]. The diagnostic testing sites included a hospital [95], a school [87], a speech
11 and hearing centre [91], and a telemedicine platform[8,85].
12
13
14

15 16 **Utilization of ICT**

17
18
19 In studies related to newborn and infant hearing screening, three programs reported the use of ICT for storing
20 and forwarding results [34], database management [39,57], and sending reminders for follow-up screening.
21
22

23 In studies reporting screening of older children, five studies reported using telepractice for screening,
24 diagnosis, or both. Tele-diagnostic ABR [84,85] was reported in India. use of m-health-based automated
25 hearing screening was reported in China by Wu et al. (2013) and Kam et al. (2014) a tele- sensory screening
26 platform including hearing screening (SZOK paradigm) in Tajikistan, where both screening and diagnosis
27 were carried out via telemedicine [8].
28
29
30
31

32 33 **Validity and efficacy of the screening programs:**

34
35
36 Validity of screening programs as reported in the studies was evaluated based on three criteria: use of a
37 validated screening tool, use of a validated diagnostic tool, whether the program was in design phase or in
38 implementation phase.
39
40

41
42 Among the studies that reported newborn and infant hearing screening, 48 studies fulfilled all 3 criteria of the
43 validity tool; Eleven studies fulfilled 2 out of 3 criteria; Six studies fulfilled 1 out of 3 criteria (Figure 2A).
44 Validated screening tool was used by sixty three studies and fifty four studies used a validated diagnostic tool.
45 As per the criteria we used, fifty five studies could be classified to be in the implementation phase and ten
46 studies were in design phase.
47
48
49

50
51 Economic analysis, frequency of identification and intervention were the 3 criteria included to assess efficacy.
52 Only two studies fulfilled all the three efficacy criteria, seventeen studies fulfilled two out of the three criteria,
53 thirty seven studies fulfilled only one of the three criteria, whereas remaining nine studies did not fulfil any of
54 the criteria. Fifty one studies only reported the frequency of identification, whereas fourteen reported both the
55 frequency of identification and intervention. Twelve percent of the studies did not mention either of these
56 outcomes. Economic analysis was very limited (n=3) and were reported majorly in public programs.
57
58
59
60

Among the studies that reported screening programs for older children, ten studies fulfilled all the three criteria, three studies fulfilled two out of three criteria, three studies fulfilled one out of three criteria. Only one study did not meet any of the criteria [83] a questionnaire and an otoscopic examination to estimate the incidence of conductive hearing loss in older children.

With respect to efficacy it was observed that none of the studies among older children fulfilled all the three criteria. Only five studies fulfilled two out of three criteria whereas the remaining twelve studies fulfilled only one criterion.

Fourteen studies have reported frequency of identification, but only five studies have reported the frequency of intervention (e.g. medical intervention for conductive pathology). The intervention related screening programs were reported from India, China and Turkey. The economic analysis was only reported in two studies [84,91]. Except for the economic analysis, only two of the 17 studies fulfilled all validity and efficacy criteria [85,88].

Prevalence of hearing loss

Across 48 studies, the mean prevalence of hearing loss among newborns and infants was 5/1000 in India, 2/1000 in China, 2/1000 in other Southeast Asian nations (Thailand, Malaysia and Nepal), 2/1000 in Turkey, and 4/1000 in Iran. Figure 3 (A to E) shows the forest plots for prevalence of each country.

In screening programs for older children, 11 programs reported percentage of hearing loss including both conductive and sensory neural hearing loss. The outcomes are reported in Table 3.

Table 3: Secondary outcomes: Studies reporting percentage of conductive and sensorineural hearing loss in older children in each country

| Country | Author and year | Sample size | No. of CDHL | % of CDHL | No. of SNHL | % of SNHL | Overall HL | % of HL | LB (CI: 95%) | UB (CI: 95%) |
|------------|---------------------------|-------------|-------------|-----------|-------------|-----------|------------|---------|--------------|--------------|
| India | Chadha et al.,2012 | 15718 | 1578 | 10.03% | NA | NA | 1578 | 10.30% | 9.57% | 10.52% |
| | Shekhar et al., 2020 | 474 | 146 | 30.60% | 1 | 0.20% | 147 | 31.01% | 26.87% | 35.39% |
| Turkey | Tokgöz-Yılmaz et al.,2013 | 239 | 25 | 10.40% | 1 | 0.40% | 26 | 10.88% | 7.23% | 15.53% |
| | Kaplama et al.,2020 | 23664 | 186 | 0.78% | 89 | 0.37% | 275 | 1.16% | 1.03% | 1.31% |
| Iran | TarvijEslami et al.,2017 | 2284 | 28 | 1.22% | 8 | 0.35% | 36 | 1.58% | 1.11% | 2.18% |
| | Jalali et al.,2020 | 2019 | 19 | 0.94% | 8 | 0.39% | 27 | 1.34% | 0.88% | 1.94% |
| Tajikistan | Pilka et al.,2016 | 143 | NA | NA | NA | NA | 34 | 23.70% | 17.06% | 31.61% |
| Jordan | Alaqrabawi et al.,2016 | 1649 | 54 | 3.27% | 36 | 2.18% | 90 | 5.46% | 4.41% | 6.61% |
| Iraq | Al-Obeidy et al.,2019 | 425 | 28 | 6.59% | 2 | 0.47% | 30 | 7.06% | 4.81% | 9.92% |
| China | Lu et al.,2011 | 21547 | 285 | 1.32% | 16 | 0.07% | 301 | 1.40% | 1.24% | 1.56% |
| | Chen et al 2012 | 28546 | 344 | 1.21% | 22 | 0.08% | 366 | 1.28% | 1.15% | 1.42% |

Abbreviations: CDHL: Conductive Hearing Loss; SNHL: Sensori Neural Hearing Loss; HL: Hearing Loss; LB: Lower Bound; UB: Upper Bound

Barriers and facilitators:

Barriers:

Loss to follow-up for second screening and diagnostics [18,25,29,35–37,42,55,58,59,62,64,66,72,73] was reported as a major challenge. Loss to follow up was linked to parental rejection for diagnosis [23,26,59], poor tracking system [42,73], financial burden of parents, low socioeconomic status[70] and travel distance to testing distance. Other major challenges highlighted in relation to outcomes included limited coverage [30,35], and a high referral rate [24,25,37], poor long-term outcomes with respect to coverage and referral rate [46].

Other factors that had an indirect impact on programme outcomes included the lack of dedicated screening personnel [23]; lack of professional resources/audiologists[73,80]; high ambient noise in the testing environment [30]; and the absence of diagnostic facilities [62]. A few studies mentioned challenges affecting programme implementation, such as the use of a three-step protocol only with OAE [60]; the difficulties of centralised programme implementation in remote locations [73] and delay in diagnosis in remote locations due to referral to regional facilities [80].

In screening for older children, children's attention was regarded as a major challenge resulting in poor accuracy [91]. Other key factors influencing programme outcomes included inadequate internet connectivity [8,85]; poor follow-up due to social stigma.

Facilitators:

Use of appropriate tracking or data management systems, were reported to be helpful in minimising lost-to-follow-up[18,26,35,42,57]. Combining hearing screening with other screenings improved follow-up rates [47,81]. Several studies highlighted strategies to minimise false referral rates, including: i) employing a conducive environment and trained individuals [25]; ii) adding AABR in the initial stage of screening protocol [41]; screening between 3 and 5 days of age [81]; and incorporating tympanometry into the screening protocol [33]. Financial assistance in the form of funding [37,39,57]; and centralised hearing screening facilities or grouping more centres [18,26] were strategies reported in studies to improve coverage rates. Multi-centre based or a centralised hearing screening program was reported to be resource efficient with respect to cost, infrastructure and professionals [18].

DISCUSSION

The primary purpose of this review was to describe the models of hearing screening programmes implemented in young children in various Asian LMICs in the published scientific literature. Out of more than one hundred LMICs, only 14 countries in Asia reported hearing screening programs that fit our inclusion criteria. In a recent systematic review, high quality literature with hearing screening programs was

1 reported to be primarily in high income countries [98], yet, it is also likely that resources for research and
2 publication is low and hence is also low on priority in the LMIC context. Our review gathered evidence on
3 hearing screening programmes in general, including screening protocols, screening tests, pass/fail criteria,
4 screening personnel, diagnostic tests, use of ICT, and programme validity and efficacy.
5
6

7 The hearing screening tools and protocols utilised for newborns, infants, and older children were similar to
8 those used in high-income countries [99]. Despite the fact that the majority of programmes used a two-stage
9 OAE(DP/TE) and ABR screening as preferred screening tools across countries, there was no consistency in
10 protocol stages or screening tests undertaken. This was consistent with Kanji et al. (2018)'s assessment of
11 NHS protocols, which revealed non-uniformity in the protocols followed.
12
13

14 It was also noted that objective hearing screening was most commonly reported over subjective hearing
15 screening for newborns and infants. Only one study [20] found good sensitivity and specificity for
16 behavioural hearing assessment for neonates and infants using calibrated noise makers. The use of objective
17 screening in LMICs implies a preference for international best practices based on Western contexts and
18 guidelines [2] However, it is important to assess the sustainability and long term outcomes of these efforts.
19 Subjective single stage PTA screening, on the other hand, was extensively used in various screening
20 programmes for older children above the age of three. This is comparable to high-income countries where
21 PTA screening is mandatory for children over the age of three [100,101]. In contrast, the current review
22 found a few public initiatives [29,54,97] that used questionnaire methods and this implies that mass screening
23 was being done by low cost tools like questionnaires where resources were limited.
24
25

26 Audiologists were the most common screening personnel in newborn screening programmes across Asian
27 LMICs. This is in contrast to HICs, where nurses mostly performed hearing screening [102]. While the
28 majority of NHS programmes in Asian LMICs were started by audiologists or otolaryngologists in private
29 hospitals, in most HICs the screening programmes were generally universal and followed as a part of other
30 normal newborns screening before discharge. Screening of older children was mostly done by
31 otolaryngologists, school instructors, and nurses. This could be because many of the screening programmes
32 for older children were conducted in schools or community settings in the absence of audiologists on-site. In
33 contrast, hearing screenings are carried out at child health clinics by a dedicated school nurse/audiologist in
34 high income countries [102].
35
36

37 Use of the test battery was limited in diagnostic confirmation of hearing loss. Detailed ABR testing was
38 considered as the standard diagnostic tool in many countries as it examines the entire peripheral auditory
39 pathway responsible for hearing. Apart from this, studies from China employed a test battery containing a
40 variety of tests altogether (eg. ASSR, ABR, and tympanometry) to confirm hearing loss. In WHO guidelines
41 for hearing screening, diagnostic test battery including ABR/ASSR, tympanometry, acoustic reflex,
42 otoscopic examination and medical evaluation was suggested [103]. Therefore, in HICs the diagnostic test
43 battery approach is mostly preferred [102]. In screening programmes for older children, medical (ENT)
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 examination in cases of conductive pathology and routine PTA with or without tympanometry were
2 prioritised as tests to confirm hearing loss. This is inconsistent with the WHO guidelines [103] and with the
3 programs from high income countries [102].
4

5
6 Few studies reported the use of ICT to screen, manage data or perform diagnostic tests [8,85]. Lack of
7 utilization of ICT could be due to lack of adequate infrastructure, skills to support use of such tools. Yet, this
8 is not unique to LMICs as evidence on use of ICT is limited even among high income countries
9 [98,99,102,104].
10
11

12
13 We assessed the validity and efficacy of the screening programme for infants and older children using a
14 purposively developed tool. None of the programmes reported met all of the criteria. The majority of
15 programmes made use of validated screening and diagnostic tools and reported the rate of hearing loss
16 identification. However, information on economic analysis was scarce, even though cost effectiveness is a
17 key variable for determining programme success [105]. Furthermore, studies predominantly only reported
18 identification but not intervention. The importance of EHDI programs is to intervene children so that the
19 pervasive impact of childhood hearing loss can be mitigated [106,107], therefore it is pertinent to know
20 whether such programmes resulted in early intervention.
21
22

23
24 Mean prevalence of hearing loss in newborns and infants was identified to be high in India (6/1000),
25 followed by Iran (3/1000) and China (2/1000). This is similar to the findings of Busse and colleagues (2021)
26 where the highest prevalence was found in India and Nigeria, followed by Iran. In another review,
27 prevalence was found to be highest in Asian countries compared to other regions [104]. A world report on
28 hearing (WHO, 2021) also stated that prevalence of congenital hearing loss in LMIC is high compared to
29 HICs.
30
31

32
33 Barriers identified from our review were similar to those previously identified and discussed in various
34 studies including LMICs [102,106,107,109]. However, a recent study in HICs found that when hearing
35 screening programmes were integrated as part of national screening with a dedicated screening person,
36 database management system, and appropriate guidelines, they were more successful. Therefore, EHDI in
37 LMIC is also likely to be more successful when implemented through the government.
38
39

40
41 There were some limitations to the review which must be considered. No article was excluded based on
42 quality assessment owing to the limited literature available from LMICs, yet the risk of bias in many
43 included studies was moderate to high. Furthermore, due to a lack of quantitative data and heterogeneity in
44 the information obtained across studies, no meta-analysis was performed. The generalisability of the
45 findings was limited to Asian LMICs. Further, there were potential for publication bias as not all
46 programmes would have published their results. The coverage of EHDI in these countries was not assessed.
47
48

49
50 From this study, it is evident that strategies for EHDI in Asian LMICs were similar to those recommended in
51 HICs. However, there is inadequate evidence related to the intended outcome of early intervention in this
52
53
54
55
56
57
58
59
60

context. Therefore, program planners and researchers must focus on impact evaluations that demonstrate the long term viability of EHDI programs in the LMIC context.

FIGURES

Figure 1: PRISMA flowchart representing the selection of article at each stage

Figure 2A: Validity and efficacy of screening programs for newborns and infants

Figure 2B: Validity and efficacy of screening programs for older children

Figure 3A: Forest plot of prevalence of hearing loss in newborns and infants in India

Figure 3B: Forest plot of prevalence of hearing loss in newborns and infants in India

Figure 3C: Forest plot of prevalence of hearing loss in newborns and infants in China

Figure 3D: Forest plot of prevalence of hearing loss in newborns and infants in Turkey

Figure 3E: Forest plot of prevalence of hearing loss in newborns and infants in Iran

Conflict of interest: There is no conflict of interest associated with this study.

Funding statement: This review received in-part support from DBT/Wellcome Trust India Alliance (IA/CPHI/19/1/504614)

REFERENCES

- 1 World Health Organization (WHO). Deafness and Hearing Loss. 2021.
- 2 Busa J, Harrison J, Chappell J, *et al.* Year 2007 position statement: Principles and guidelines for early hearing detection and intervention programs. *Pediatrics* 2007;**120**:898–921.
- 3 Krishnan LA, Donaldson LK. Newborn Hearing Screening in Developing Countries: Understanding the Challenges and Complexities of Implementation. *Perspectives on Global Issues in Communication Sciences and Related Disorders* 2013;**3**:54.
- 4 Kanji A, Khoza-Shangase K. In pursuit of successful hearing screening: An exploration of factors associated with follow-up return rate in a risk-based newborn hearing screening programme. *Iran J Pediatr* 2018;**28**.
- 5 Louw B, Swanepoel DW. Infant hearing screening at immunization clinics in South Africa. *Int J Pediatr Otorhinolaryngol* 2006;**70**:1241–9.
- 6 de Kock T, Swanepoel DW, Hall JW. Newborn hearing screening at a community-based obstetric unit: Screening and diagnostic outcomes. *Int J Pediatr Otorhinolaryngol* 2016;**84**:124–31.
- 7 Friderichs N, Swanepoel D, 3rd HJW. Efficacy of a community-based infant hearing screening program utilizing existing clinic personnel in Western Cape, South Africa. *Int J Pediatr Otorhinolaryngol* 2012;**76**:552–9.

- 1 8 Piłka A, Skarżynska MB, Włodarczyk AW, *et al.* A Hearing Screening Program for Children in Primary
2 Schools in Tajikistan : A Telemedicine Model. 2016;:2424–30.
- 3 9 Monica SD, Ramkumar V, Krumm M, *et al.* School entry level tele-hearing screening in a town in South India
4 – Lessons learnt. *Int J Pediatr Otorhinolaryngol* 2017;**92**:130–5.
- 5
6 10 Dharmar M, Simon A, Sadorra C, *et al.* Reducing Loss to Follow-Up with Tele-audiology Diagnostic
7 Evaluations. *Telemedicine and e-Health* 2016;**22**:1–6.
- 8
9 11 Yousuf Hussein S, Swanepoel DW, Mahomed F, *et al.* Community-based hearing screening for young children
10 using an mHealth service-delivery model. *Glob Health Action* 2018;**11**.
- 11
12 12 2Dsearch. <https://www.2dsearch.com/> (accessed 8 Oct 2022).
- 13
14 13 Ouzzani M, Hammady H, Fedorowicz Z, *et al.* Rayyan-a web and mobile app for systematic reviews. *Syst Rev*
15 2016;**5**:1–10.
- 16
17 14 Page MJ, McKenzie JE, Bossuyt PM, *et al.* The PRISMA 2020 statement: An updated guideline for reporting
18 systematic reviews. *The BMJ* 2021;**372**.
- 19
20 15 Critical Appraisal Tools | JBI. <https://jbi.global/critical-appraisal-tools> (accessed 8 Oct 2022).
- 21
22 16 Campbell M, McKenzie JE, Sowden A, *et al.* Synthesis without meta-analysis (SWiM) in systematic reviews:
23 reporting guideline. *BMJ* 2020;**20**:16890.
- 24
25 17 Biswas AK, Goswami SC, Baruah DK, *et al.* The Potential Risk Factors and the Identification of Hearing Loss
26 in Infants. *Indian Journal of Otolaryngology and Head and Neck Surgery* 2012;**64**:214–7.
- 27
28 18 AK P. Early identification of hearing loss and centralized newborn hearing screening facility-the Cochin
29 experience. *Indian Pediatr* 2011;**48**:355–9.
- 30
31 19 Mishra G, Sharma Y, Mehta K, *et al.* Efficacy of Distortion Product Oto-Acoustic Emission (OAE)/Auditory
32 Brainstem Evoked Response (ABR) Protocols in Universal Neonatal Hearing Screening and Detecting Hearing
33 Loss in Children <2 Years of Age. *Indian Journal of Otolaryngology and Head and Neck Surgery*
34 2013;**65**:105–10.
- 35
36 20 Ramesh A, Jagdish C, Nagapoorinima M, *et al.* Low cost calibrated mechanical noisemaker for hearing
37 screening of neonates in resource constrained settings. *Indian J Med Res.* 2012;**135**:170–6.
- 38
39 21 Rai N, Thakur N. Universal screening of newborns to detect hearing impairment-Is it necessary? *Int J Pediatr*
40 *Otorhinolaryngol* 2013;**77**:1036–41.
- 41
42 22 Kumar A, Shah N, Patel KB, *et al.* Hearing screening in a tertiary care hospital in India. *Journal of Clinical*
43 *and Diagnostic Research* 2015;**9**:MC01–4.
- 44
45 23 Gupta S, Sah S, Som T, *et al.* Challenges of Implementing Universal Newborn Hearing Screening at a Tertiary
46 Care Centre from India. *Indian J Pediatr* 2015;**82**:688–93.
- 47
48 24 Vignesh SS, Jaya V, Sasireka BI, *et al.* Prevalence and referral rates in neonatal hearing screening program
49 using two step hearing screening protocol in Chennai - A prospective study. *Int J Pediatr Otorhinolaryngol*
50 2015;**79**:1745–7.
- 51
52 25 Vishwakarma C, Mathur R, Vishwakarma R, *et al.* Universal hearing screening vs targetted hearing screening:
53 Make a choice. *Indian Journal of Otology* 2015;**21**:179–82.
- 54
55 26 Paul AK. Centralized Newborn Hearing Screening in Ernakulam, Kerala , Experience Over a Decade. *Indian*
56 *Pediatr* 2016;**53**:15–7.
- 57
58 27 Sharma Y, Bhatt SH, Nimbalkar S, *et al.* Non-compliance With Neonatal Hearing Screening Follow-up in
59 Rural Western India. *Indian Pediatr* 2018;**55**:482–4.
- 60
28 Kumar P, Adhisivam B, Vishnu Bhat B, *et al.* Screening for hearing loss among high risk neonates–
Experience from a tertiary care center. *Current Pediatric Research* 2016;**20**:43–6.

- 29 Sachdeva K, Sao T. Outcomes of Newborn Hearing Screening Program: A Hospital Based Study. *Indian Journal of Otolaryngology and Head and Neck Surgery* 2017;**69**:194–8.
- 30 Kumar A, Gupta SC, Sinha VR. Universal Hearing Screening in Newborns Using Otoacoustic Emissions and Brainstem Evoked Response in Eastern Uttar Pradesh. *Indian Journal of Otolaryngology and Head and Neck Surgery* 2017;**69**:296–9.
- 31 Swain SK, Das A, Sahu MC, *et al.* Neonatal hearing screening: Our experiences at a tertiary care teaching hospital of eastern India. *Pediatr Pol* 2017;**92**:711–5.
- 32 Bhat J, Kurmi R, Kumar S, *et al.* Targeted screening for hearing impairment in neonates: A prospective observational study. *Indian Journal of Otology* 2018;**24**:42–6.
- 33 Bishnoi R, Baghel S, Agarwal S, *et al.* Newborn Hearing Screening: Time to Act! *Indian Journal of Otolaryngology and Head and Neck Surgery* 2019;**71**:1296–9.
- 34 Parab SR, Khan MM, Kulkarni S, *et al.* Neonatal Screening for Prevalence of Hearing Impairment in Rural Areas. *Indian Journal of Otolaryngology and Head and Neck Surgery* 2018;**70**:380–6.
- 35 Jacob J, Kurien M, Sindhusa, *et al.* Challenges of Universal Newborn Hearing Screening in a Developing Country-a Double-Edged Sword. *Indian Journal of Otolaryngology and Head and Neck Surgery* 2020;1-7.
- 36 Nishad A, Gangadhara Somayaji KS, Mithun HK, *et al.* A study of incidence of hearing loss in newborn, designing a protocol and methodology to detect the same in a tertiary health-care center. *Indian Journal of Otology* 2020;**26**:85–8.
- 37 Sija S, Gireesan VK, Kumar A, *et al.* Outcome of a Newborn Hearing Screening Program in a Tertiary Care Center , South India. *The Journal of Early Hearing Detection and Intervention* 2022;**7**:101–7.
- 38 Zhang Z, Ding W, Liu X, *et al.* Auditory screening concurrent deafness predisposing genes screening in 10,043 neonates in Gansu province, China. *Int J Pediatr Otorhinolaryngol* 2012;**76**:984–8.
- 39 Tobe RG, Mori R, Huang L, *et al.* Cost-Effectiveness Analysis of a National Neonatal Hearing Screening Program in China: Conditions for the Scale-Up. *PLoS One* 2013;**8**.
- 40 Chen G, Yi X, Chen P, *et al.* A large-scale newborn hearing screening in rural areas in China. *Int J Pediatr Otorhinolaryngol* 2012;**76**:1771–4.
- 41 Shang Y, Hao W, Gao Z, *et al.* An effective compromise between cost and referral rate: A sequential hearing screening protocol using TEOAEs and AABRs for healthy newborns. *Int J Pediatr Otorhinolaryngol* 2016;**91**:141–5.
- 42 Wenjin W, Xiangrong T, Yun L, *et al.* Neonatal hearing screening in remote areas of China: a comparison between rural and urban populations. *J Int Med Res.* 2018;**46**:637–51.
- 43 Wang Q, Xiang J, Sun J, *et al.* Nationwide population genetic screening improves outcomes of newborn screening for hearing loss in China. *Genetics in Medicine* 2019;**21**:2231–8.
- 44 Dai P, LH H, GJ W, *et al.* Concurrent Hearing and Genetic Screening of 180,469 Neonates with Follow-up in Beijing, China. *Am J Hum Genet* 2019;**105**:803–12.
- 45 Zeng X, Liu Z, Wang J, *et al.* Combined hearing screening and genetic screening of deafness among Hakka newborns in China. *Int J Pediatr Otorhinolaryngol* 2020;**136**.
- 46 Wen C, Li X, Huang L, *et al.* Current status of universal newborn hearing screening program at 26 institutions in China. *Int J Pediatr Otorhinolaryngol* 2020;**138**.
- 47 Guo L, Xiang J, Sun L, *et al.* Concurrent hearing and genetic screening in a general newborn population. *Hum Genet.* 2020;**139**:521–30.
- 48 Guomei C, Luyan Z, Lingling D, *et al.* Concurrent Hearing and Genetic Screening among Newborns in Ningbo, China. *Comput Math Methods Med* 2022;**2022**.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
- Ahmad A, Mohamad I, Mansor S, *et al.* Outcome of a newborn hearing screening program in a tertiary hospital in Malaysia: the first five years. *Ann Saudi Med* 2011;**31**:24–8.
- Wong Y, Mazlan R, ... NAW-J of M, *et al.* Quality measures of a multicentre universal newborn hearing screening program in Malaysia. *Journal of medical screening*, 28; **3**:238-243.
- Tungvachirakul V, Boonmee S, Nualmoosik T, *et al.* Newborn hearing screening at Rajavithi Hospital, Thailand: hearing loss in infants not admitting in intensive care unit. *J Med Assoc Thai* 2011;**94** Suppl 2.
- Poonual W, Navacharoen N, Kangsanarak J, *et al.* Risk factors for hearing loss in infants under universal hearing screening program in Northern Thailand. *J Multidiscip Healthc* 2016;**9**:1–5.
- Poonual W, Navacharoen N, Kangsanarak J, *et al.* Outcome of early identification and intervention on infants with hearing loss under universal hearing screening program. *Journal of the Medical Association of Thailand* 2017;**100**:197–206.
- Poonual W, Navacharoen N, Kangsanarak J, *et al.* Hearing loss screening tool (COBRA score) for newborns in primary care setting. *Korean J Pediatr* 2017;**60**:353–8.
- Pitathawatchai P, Khaimook W, Kirtsreesakul V. Pilot implementation of newborn hearing screening programme at four hospitals in southern Thailand. *Bull World Health Organ* 2019;**97**:663–71.
- Ray P, Thakali S, Prajapati S. Newborn Hearing Screening: Experience from a Tertiary level Hospital in Nepal. *Nepal Medical Journal* 2021;**4**:33–6.
- Mazlan R, Raman K, Abdullah A. A 10 - year retrospective analysis of newborn hearing screening in a tertiary hospital in Malaysia. *The Egyptian Journal of Otolaryngology* 2022;**38**.
- Shameem M, Saha KL, Uddin MB, *et al.* Hearing Screening to Evaluate the Status of Newborn Hearing Impairment in the NICU of a Tertiary Hospital. *TAJ: Journal of Teachers Association* 2022;**35**:77–82.
- Khaimook W, Suwanno R, Dindamrongkul R, *et al.* An Early Hearing Detection and Intervention Program in Songklanagarind Hospital. *Journal of Health Science and Medical Research* 2022;**40**:551–9.
- Tasci Y, Muderris II, Erkaya S, *et al.* Newborn hearing screening programme outcomes in a research hospital from Turkey. *Child Care Health Dev* 2010;**36**:317–22.
- Sennaroglu G, Akmese PP. Risk factors for hearing loss and results of newborn hearing screening in rural area. *J Int Adv Otol* 2011;**7**:343.
- Ulusoy S, Ugras H, Cingi C, *et al.* The results of national newborn hearing screening (NNHS) data of 11,575 newborns from west part of Turkey. *Eur Rev Med Pharmacol Sci* 2014;**18**:2995–3003.
- Kemaloğlu Y, Gökdoğan Ç, ... BG-EA of, *et al.* Newborn hearing screening outcomes during the first decade of the program in a reference hospital from Turkey. *European Archives of Oto-Rhino-Laryngology* 2016; **273**: 1143-1149.
- Yorulmaz A, Genç U, Yılmaz FH, *et al.* Evaluation and importance of our newborn hearing screening results. *Haseki Tip Bulteni* 2017;**55**:111–8.
- Çelik O, Eskiizmir G, Uz U. A comparison of thresholds of auditory steady-state response and auditory brainstem response in healthy term babies. *Journal of International Advanced Otolology* 2016;**12**:277–81.
- Öztürk S, Aktaş S, ... LK-TA of, *et al.* The follow-up results of newborn hearing screening of Gaziosmanpasa Taksim Research and Training Hospital. *Turkish Archives of Pediatrics/Türk Pediatri Arşivi*, 2018; **53**: 1
- Hamdi A. Evaluation of 1808 Newborns Hearing Screening Outcome. *Eurasian J Med Oncol* Published Online First: 2018.
- Yücel A, Alataş N, Yücel H, *et al.* Newborn hearing screening results of refugees living in our city and the factors affecting the results. *Int J Pediatr Otorhinolaryngol* 2019;**123**:187–90.
- Arslan S, Işık AÜ, Imamoğlu M, *et al.* Universal newborn hearing screening; Automated transient evoked otoacoustic emissions. *B-ENT* 2013;**9**:123–31.


- 70 Çıkrıkçı S, Deniz H, Gülşen S. Comparison of hearing screening results of Syrian refugees and Turkish newborns. *Int J Pediatr Otorhinolaryngol* 2020;**135**.
- 71 Arjmandi F, Farhangfar B, Mehrabi S, *et al*. Prevalence of deafness and hearing screening in newborns in Isfahan. *Journal of Research in Medical Sciences* 2012;**17**:S233–6.
- 72 Islami Z, Baradaranfar M-H, Mehrparvar A-H, *et al*. Frequency of hearing impairment among full-term newborns in Yazd, Iran. *Iran J Pediatr* 2013;**23**:349–52.
- 73 Firoozbakht M, Mahmoudian S, Alaeddini F, *et al*. Community-based newborn hearing screening programme for early detection of permanent hearing loss in Iran: An eight-year cross-sectional study from 2005 to 2012. *J Med Screen* 2014;**21**:10–7.
- 74 Zahed Y, Zamani ; Mohammad, Hashemi A, *et al*. Screening of Hearing in Newborn Infants: Follow-Up and Outcome After 40 930 Births in Babol, Northern Iran. 2018.
- 75 Farhat AS, Ghasemi MM, Akhondian J, *et al*. Assessment of the prevalence of hearing impairment in neonates born in Imam Reza, Ghaem and OM-Albanin Hospitals of Mashhad. *Iranian Journal of Neonatology* 2014;**5**:17–20.
- 76 Haghshenas M, Fard H, Delavari K, *et al*. Auditory screening in infants for early detection of permanent hearing loss in northern Iran. *Ann Med Health Sci Res* 2014;**4**:340.
- 77 Baradaranfar MH, Mehrparvar AH, Mostaghaci M, *et al*. Hearing abnormality in Neonate Intensive Care Unit (NICU), Yazd-Iran. *Int J Pediatr* 2014;**2**:113–7.
- 78 Azizi A, Amirian F, Dargahi A, *et al*. Evaluation of universal newborn hearing screening with TEOAE and ABR: A cross-sectional study with the literature review. *International Journal of Tropical Medicine* 2016;**11**:84–9.
- 79 Tajik S, Ahmadpour-Kacho M. Early diagnosis and intervention for hearing loss in newborns discharged from intensive care units: A four-year follow-up study in North of Iran. *Int J Pediatr* 2016;**4**:3283–91.
- 80 Saki N, Bayat A, Hoeinabadi R, *et al*. Universal newborn hearing screening in southwestern Iran. *Int J Pediatr Otorhinolaryngol* 2017;**97**:89–92.
- 81 Rahimi V, Mohammadkhani G, Javadi F. Improving universal newborn hearing screening outcomes by conducting it with thyroid screening. *Int J Pediatr Otorhinolaryngol* 2018;**111**:111–4.
- 82 Tuli IP, Pal I, Sengupta S, *et al*. Role of early audiological screening and intervention. *Indian Journal of Otology* 2012;**18**:148–53.
- 83 Chadha SK, Sayal A, Malhotra V, *et al*. Prevalence of preventable ear disorders in over 15 000 schoolchildren in northern India. *Journal of Laryngology and Otology* 2013;**127**:28–32.
- 84 Ramkumar V, John KR, Selvakumar K, *et al*. Cost and outcome of a community-based paediatric hearing screening programme in rural India with application of tele-audiology for follow-up diagnostic hearing assessment. *Int J Audiol* 2018;**57**:407–14.
- 85 Ramkumar V, Nagarajan R, Shankarnarayan VC, *et al*. Implementation and evaluation of a rural community-based pediatric hearing screening program integrating in-person and tele-diagnostic auditory brainstem response (ABR). *BMC Health Serv Res* 2019;**19**.
- 86 Verma PK, Chopra D, Khwaja M, *et al*. Prevalence of Hearing Impairment in School Children in A Rural area of Lucknow- A Cross Sectional Study. *International Journal of Pharmaceutical and Clinical Research* 2022;**14**:80–4.
- 87 Shekhar H, Khokhar A, Motwani G, *et al*. Prevalence of ear morbidities among school children in Delhi, India: a cross-sectional study. *Int J Adolesc Med Health* Published Online First: 2020.
- 88 Lü J, Huang Z, Yang T, *et al*. Screening for delayed-onset hearing loss in preschool children who previously passed the newborn hearing screening. *Int J Pediatr Otorhinolaryngol* 2011;**75**:1045–9.

- 1 89 Chen G, Fu S, Luo S, *et al.* Screening of delayed-onset hearing loss in preschool children in the mid-south of
2 China. *Int J Audiol* 2013;**52**:568–71.
- 3 90 Wu W, Lü J, Li Y, *et al.* A new hearing screening system for preschool children. *Int J Pediatr*
4 *Otorhinolaryngol* 2014;**78**:290–5.
- 5 91 Kam ACS, Li LKC, Yeung KNK, *et al.* Automated hearing screening for preschool children. *J Med Screen*
6 2014;**21**:71–5.
- 7 92 Tokgöz-Yılmaz S, Özcebe E, MD T, *et al.* Evaluation of hearing and speech-language in preschool children:
8 how important, why we should perform? *Turk J Pediatr* 2013;**55**:606–11.
- 9 93 Kaplama ME, Ak S. The results of hearing screening in refugee school children living in Şanlıurfa /Turkey and
10 the related risk factors. *Int J Pediatr Otorhinolaryngol* 2020;**134**.
- 11 94 TarvijEslami S, Nassirian H, Bayesh S. Impact on performance of hearing screening program through
12 prevalence and diagnostic age evaluation in elementary school students in north-eastern city of Iran, Mashhad.
13 *Pediatr Pol* 2017;**92**:705–10.
- 14 95 Jalali MM, Nezamdoust F, Ramezani H, *et al.* Prevalence of hearing loss among school-age children in the
15 north of Iran. *Iran J Otorhinolaryngol* 2020;**32**:85–92.
- 16 96 Alaqrabawi WS, Alshwabka AZ, Al-Addasi ZM, *et al.* What are the predictive causes of conductive hearing
17 loss in school-age children in Jordan? *Jordan Med J* 2016;**50**:187–94.
- 18 97 Al-Obeidy SH, Abdulrahman ZN, Zaradwy IAR. School-entry Screening Program for Ear and Hearing
19 Problems in Tikrit, Iraq. *Middle East Journal of Family Medicine* 2019;**17**.
- 20 98 Yoshinaga-Itano C, Manchaiah V, Hunnicutt C. Outcomes of Universal Newborn Screening Programs:
21 Systematic Review. *J Clin Med* 2021;**10**:2784.
- 22 99 Kanji A, Khoza-Shangase K, Moroe N. Newborn hearing screening protocols and their outcomes: A systematic
23 review. *Int J Pediatr Otorhinolaryngol.* 2018;**115**:104–9.
- 24 100 Bright, K., Greeley, C.O., Eichwald, J., Loveland, C.O. and Tanner, G., American Academy of Audiology
25 childhood hearing screening guidelines. Reston, VA: American Academy of Audiology Task Force. 2011.
- 26 101 Childhood Hearing Screening. <https://www.asha.org/practice-portal/professional-issues/childhood-hearing-screening/>
27 (accessed 7 Oct 2022).
- 28 102 Bussé AML, Mackey AR, Carr G, *et al.* Assessment of hearing screening programmes across 47 countries or
29 regions III: provision of childhood hearing screening after the newborn period. *Int J Audiol* 2021;**60**:841–8.
- 30 103 World Health Organization. Hearing screening: considerations for implementation. World Health
31 Organization. 2021.
- 32 104 Butcher E, Dezateux C, Cortina-Borja M, *et al.* Prevalence of permanent childhood hearing loss detected at the
33 universal newborn hearing screen: Systematic review and metaanalysis. *PLoS One* 2019;**14**:1–21.
- 34 105 Colgan S, Gold L, Wirth K, *et al.* The cost-effectiveness of universal newborn screening for bilateral
35 permanent congenital hearing impairment: Systematic review. *Acad Pediatr* 2012;**12**:171–80.
- 36 106 Neumann K, Chadha S, Tavartkiladze S *et al.* Newborn and infant hearing screening facing globally growing
37 numbers of people suffering from disabling hearing loss. *International Journal of Neonatal Screening* 2019; **5**:1
- 38 107 Olusanya B. Screening for neonatal deafness in resource-poor countries: challenges and solutions. *Res Rep*
39 *Neonatal* 2015;:51.
- 40 108 OM da S. World Report On Hearing. *World Health Organization* 2021;:1–272.
- 41 109 Galhotra A, Sahu P. Challenges and solutions in implementing hearing screening program in India. *Indian*
42 *Journal of Community Medicine* 2019;**44**:299–302.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Confidential: For Review Only

Figure 1 : PRISMA Flowchart representing selection of studies at different levels of screening



Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

| Citation | Country | Validity of the screening program | | | Efficacy of the screening program | | |
|-------------------------------|------------|-----------------------------------|--|--|-----------------------------------|-----------------------------|---------------------------|
| | | Use of validated screening tools | Valid diagnostic testing tools within the scope of the program | Implementation in phase Outcome of HL identification/ intervention or impact evaluation > 2 years duration | Program's economic analysis | Frequency of identification | Frequency of intervention |
| Biswas et al., 2012 | India | | | | | | |
| Paul et al., 2011 | India | | | | | | |
| Sharma et al., 2013 | India | | | | | | |
| Ramesh et al., 2012 | India | | | | | | |
| Rao & Tahir et al., 2013 | India | | | | | | |
| Kumar et al., 2015 | India | | | | | | |
| Gupta et al., 2015 | India | | | | | | |
| Vignesh et al., 2015 | India | | | | | | |
| Vishwakarma et al., 2015 | India | | | | | | |
| Paul et al., 2016 | India | | | | | | |
| Kumar et al., 2016 | India | | | | | | |
| Bhat et al., 2018 | India | | | | | | |
| Sachdeva & Sao et al., 2017 | India | | | | | | |
| Kumar et al., 2017 | India | | | | | | |
| Swain et al., 2017 | India | | | | | | |
| Bhat et al., 2018 | India | | | | | | |
| Bisnoi et al., 2019 | India | | | | | | |
| Parab et al., 2018 | India | | | | | | |
| Jacob et al., 2020 | India | | | | | | |
| Nishad et al., 2020 | India | | | | | | |
| Sija et al., 2022 | India | | | | | | |
| Zhang et al., 2012 | China | | | | | | |
| Huang et al., 2012 | China | | | | | | |
| Chen et al., 2012 | China | | | | | | |
| Shang et al., 2016 | China | | | | | | |
| Wenjin et al., 2018 | China | | | | | | |
| Wang et al., 2019 | China | | | | | | |
| Dai et al., 2019 | China | | | | | | |
| Zeng et al., 2020 | China | | | | | | |
| Wen et al., 2020 | China | | | | | | |
| Guo et al., 2020 | China | | | | | | |
| Guomei et al., 2022 | China | | | | | | |
| Ahmad et al., 2011 | Malaysia | | | | | | |
| Wong et al., 2020 | Malaysia | | | | | | |
| Mazlan et al., 2022 | Malaysia | | | | | | |
| Tasci et al., 2010 | Turkey | | | | | | |
| Semrangolu & Akrese, 2011 | Turkey | | | | | | |
| Ulucay et al., 2014 | Turkey | | | | | | |
| Kemaloglu et al., 2016 | Turkey | | | | | | |
| Yorulmaz et al., 2017 | Turkey | | | | | | |
| Celik et al., 2016 | Turkey | | | | | | |
| Ozturk et al., 2017 | Turkey | | | | | | |
| Hamdi, 2018 | Turkey | | | | | | |
| Yücel et al., 2019 | Turkey | | | | | | |
| Arslan et al., 2013 | Turkey | | | | | | |
| Gökriki et al., 2020 | Turkey | | | | | | |
| Ajrmandi et al., 2012 | Iran | | | | | | |
| Islami et al., 2013 | Iran | | | | | | |
| Firoozbakhshi et al., 2014 | Iran | | | | | | |
| Zahedi et al., 2014 | Iran | | | | | | |
| Farhat et al., 2014 | Iran | | | | | | |
| Haghsheenas et al., 2014 | Iran | | | | | | |
| Baradaranfar et al., 2014 | Iran | | | | | | |
| Azizi et al., 2016 | Iran | | | | | | |
| Tajik & Ahmadpour-Kacho, 2017 | Iran | | | | | | |
| Saki et al., 2017 | Iran | | | | | | |
| Rahimi et al., 2018 | Iran | | | | | | |
| Thungvachirakul et al., 2011 | Thailand | | | | | | |
| Poonual et al., 2016 | Thailand | | | | | | |
| Poonual et al., 2017b | Thailand | | | | | | |
| Poonual et al., 2017 | Thailand | | | | | | |
| Plathawatchai et al., 2019 | Thailand | | | | | | |
| Ray et al., 2021 | Nepal | | | | | | |
| Shameem et al., 2022 | Bangladesh | | | | | | |
| Khaimook et al., 2022 | Thailand | | | | | | |

Figure 2A: Validity and efficacy of hearing screening programs for newborns and infants

221x428mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


| Citation | Country | Validity of the screening program | | | Efficacy of the screening program | | |
|----------------------------|------------|-----------------------------------|--|--|-----------------------------------|------------------------|----------------------|
| | | Use of validated screening tools | Valid diagnostic testing tools within the scope of the program | Implementation phase (Outcome of HL identification/intervention or impact evaluation)> 2 years duration) | Program's economic analysis | Rate of identification | Rate of intervention |
| Tuli et al.,2012 | India | Met | Met | Met | Met | Met | Met |
| Chanda et al.,2012 | India | Met | Met | Met | Met | Met | Met |
| Shekhar et al., 2020 | India | Met | Met | Met | Met | Met | Met |
| Verma et al.,2022 | India | Met | Met | Met | Met | Met | Met |
| Lu et al.,2011 | China | Met | Met | Met | Met | Met | Met |
| Chen et al., | China | Met | Met | Met | Met | Met | Met |
| Tokgöz-Yılmaz et al., 2013 | Turkey | Met | Met | Met | Met | Met | Met |
| Kaplama et al.,2020 | Turkey | Met | Met | Met | Met | Met | Met |
| Mashhad et al.,2012 | Iran | Met | Met | Met | Met | Met | Met |
| Jalali et al.,2020 | Iran | Met | Met | Met | Met | Met | Met |
| Skarzyński et al.,2016 | Tajikistan | Met | Met | Met | Met | Met | Met |
| Alagrabawi et al.,2016 | Jordan | Met | Met | Met | Met | Met | Met |
| Al-Obeidy et al.,2019 | Iraq | Met | Met | Met | Met | Met | Met |
| Wu et al.,2013 | China | Met | Met | Met | Met | Met | Met |
| Kam et al.,2014 | China | Met | Met | Met | Met | Met | Met |
| Ramkumar et al.,2018 | India | Met | Met | Met | Met | Met | Met |
| Ramkumar et al.,2019 | India | Met | Met | Met | Met | Met | Met |
| Key | | Met criteria | | | | | |
| | | Not met criteria | | | | | |

Validity and efficacy of hearing screening programs for older children


279x215mm (150 x 150 DPI)

Figure 3 (A-E)


A. Forest plot of prevalence of hearing loss in newborns and infants in India




B. Forest plot of prevalence of hearing loss in newborns and infants in China




C. Forest plot of prevalence of hearing loss in newborns and infants in Turkey



D. Forest plot of prevalence of hearing loss in newborns and infants in Iran



E. Forest plot of prevalence of hearing loss in newborns and infants in Southeast asia



Preprint: For Review Only

Supplementary table 1: Quality appraisal for cross sectional studies using JBI tool for cross sectional studies

| Author and Year | Were the criteria for inclusion in the sample clearly defined? | Were the study subjects and the setting described in detail? | Was the exposure measured in a valid and reliable way? | Were objective, standard criteria used for measurement of the condition? | Were confounding factors identified? | Were strategies to deal with confounding factors stated? | Were the outcomes measured in a valid and reliable way? | Was appropriate statistical analysis used? |
|----------------------------|--|--|--|--|--------------------------------------|--|---|--|
| Biswas et al., 2012 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Paul et al.,2011 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Mishra et al., 2013 | Yes | Yes | NA | Yes | No | NA | Yes | No |
| Ramesh et al., 2012 | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes |
| Kumar et al.,2015 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Gupta et al.,2015 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Vignesh et al.,2015* | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Vishwakarma et al.,2015 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Paul et al.,2016 | Yes | Yes | NA | Yes | No | NA | Yes | NA |
| Sharma et al., 2018 | No | Yes | NA | Yes | No | Na | Yes | Yes |
| Kumar et al.,2016* | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Sachdeva & Sao et al.,2017 | Yes | Yes | Yes | Yes | No | NA | Yes | Yes |
| Swain et al.,2017 | Yes | Yes | Yes | Yes | No | No | Yes | Yes |
| Bhat et al.,2018 | Yes | Yes | Yes | Yes | No | NA | Yes | Yes |
| Bishnoi et al.,2018 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Parab et al.,2018 * | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Jacob et al.,2020 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Nishad et al.,2020 | Yes | Yes | NA | Yes | No | No | Yes | Yes |
| Zhang et al., 2012 | Yes | Yes | NA | Yes | No | No | No | Yes |
| Tobe et al.,2013* | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Chen et al.,2012 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Shang et al.,2016 | Yes | Yes | NA | Yes | No | NA | Yes | YEs |
| Wenjin et al., 2018 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Dai et al.,2019 | Yes | YEs | NA | Yes | No | NA | Yes | Yes |

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

| | | | | | | | | |
|----------------------------|-----|-----|-----|-----|----|----|-----|-----|
| Zeng et al., 2020 | Yes | Yes | Yes | Yes | NA | NA | Yes | Yes |
| Wen et al., 2020 * | Yes | Yes | NA | yes | No | NA | Yes | Yes |
| Guo et al., 2020 | Yes | Yes | Yes | Yes | No | NA | Yes | Yes |
| Guomei et al.,2022 | Yes | Yes | NA | Yes | No | NA | No | Yes |
| Ahmad et al.,2011 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Wong et al.,2020 | Yes | Yes | Yes | Yes | No | NA | Yes | Yes |
| Tungvachirakul et al.,2011 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Poonual et al.,2017 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Poonual et al., 2017b | Yes | Yes | Yes | Yes | No | NA | Yes | Yes |
| Pitathawatchai et al.,2019 | Yes | Yes | Yes | Yes | No | Na | Yes | Yes |
| Ray et al.,2021 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Mazlan et al.,2022 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Shameem et al., 2022 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Khaimook et al.,2022 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Sennaroglu & Akmese, 2011 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Ulusoy et al.,2014 | yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Kemaloğlu et al., 2016 | Yes | Yes | NA | Yes | No | No | Yes | Yes |
| Yorulmaz et al., 2017 | Yes | Yes | Yes | Yes | No | NA | Yes | Yes |
| Ozturk et al.,2017 | Yes | Yes | NA | Yes | No | No | Yes | Yes |
| Hamdi, 2018 | Yes | Yes | NA | Yes | No | No | Yes | Yes |
| Yücel et al., 2019 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Arslan et al., 2013 | Yes | Yes | Yes | Yes | No | NA | Yes | Yes |
| Çıkrıkçı et al., 2020* | Yes | Yes | Yes | Yes | No | NA | Yes | Yes |
| Arjmandi et al., 2012 | Yes | Yes | No | Yes | No | NA | Yes | Yes |
| Islami et al.,2013 | Yes | Yes | Yes | Yes | No | NA | Yes | Yes |
| Firoozbakht et al.,2014 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Zahed et al., 2014* | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Farhat et al., 2014 | Yes | Yes | No | Yes | No | NA | Yes | Yes |

| | | | | | | | | |
|-------------------------------|-----|-----|-----|-----|-----|-----|-----|-----|
| Haghshenas et al., 2014 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Baradaranfar et al., 2014 | Yes | Yes | Yes | Yes | No | NA | Yes | Yes |
| Azizi et al., 2016 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Tajik & Ahmadpour-Kacho, 2016 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Saki et al., 2017 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Tuli et al., 2012 | Yes | Yes | No | Yes | Yes | No | Yes | Yes |
| Chadha et al., 2013 | Yes | Yes | NA | No | Yes | Yes | Yes | Yes |
| Ramkumar et al., 2018 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Ramkumar et al., 2019 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Verma et al., 2022 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Shekhar et al., 2020 | Yes | Yes | Yes | Yes | Yes | No | Yes | Yes |
| Lu et al., 2011 | Yes | Yes | Yes | Yes | No | No | Yes | Yes |
| Chen et al., 2013 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Wu et al., 2014 | Yes | Yes | NA | No | No | NA | Yes | Yes |
| Kam et al., 2014 | Yes | Yes | NA | Yes | NA | NA | Yes | Yes |
| Tokgöz-Yılmaz et al., 2013 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Kaplama et al., 2020 | Yes | Yes | Yes | Yes | No | NA | Yes | Yes |
| TarviEslami et al., 2017 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Jalali et al., 2020 | Yes | Yes | Yes | No | No | NA | Yes | Yes |
| Pilka et al., 2016 | No | Yes | NA | Yes | No | NA | Yes | Yes |
| Alaqrabawi et al., 2016 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Al-Obeidy et al., 2019 | No | Yes | NA | No | No | NA | Yes | Yes |

Supplementary table 2: Quality appraisal for cohort studies using JBI tool for cohort study

| Were the two groups similar | Were the exposures | Was the exposure | Were confounding factors | Were strategies to deal with | Were the groups/participants free of | Were the outcomes | Was the follow up | Was follow up complete | Were strategies to address | Was appropriate statistical |
|-----------------------------|--------------------|------------------|--------------------------|------------------------------|--------------------------------------|-------------------|-------------------|------------------------|----------------------------|-----------------------------|
|-----------------------------|--------------------|------------------|--------------------------|------------------------------|--------------------------------------|-------------------|-------------------|------------------------|----------------------------|-----------------------------|

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

| | and recruited from the same population? | measured similarly to assign people to both exposed and unexposed groups? | measured in a valid and reliable way? | identified? | confounding factors stated? | the outcome at the start of the study (or at the moment of exposure)? | measured in a valid and reliable way? | time reported and sufficient to be long enough for outcomes to occur? | e, and if not, were the reasons to loss to follow up described and explored? | incomplete follow up utilized? | analysis used? |
|---------------------|---|---|---------------------------------------|-------------|-----------------------------|---|---------------------------------------|---|--|--------------------------------|----------------|
| Doon et al., 2016 | Yes | Yes | Yes | No | NA | Yes | Yes | Yes | Yes | No | Yes |
| Sija et al., 2022 | Yes | Yes | NA | No | NA | Yes | Yes | Yes | Yes | No | Yes |
| Rahimi et al., 2018 | Yes | Yes | Yes | No | NA | Yes | Yes | Yes | No | No | Yes |
| Celik et al., 2016 | Yes | Yes | Yes | No | No | Yes | Yes | Yes | Yes | Yes | Yes |
| Tasci et al., 2010 | Yes | Yes | Yes | No | NA | Yes | Yes | Yes | Yes | Yes | Yes |
| Wang et al., 2019 | Yes | Yes | Yes | No | NA | Yes | yes | Yes | Yes | Yes | Yes |
| Kumar et al., 2017 | Yes | Yes | Yes | No | NA | Yes | Yes | Yes | Yes | Yes | Yes |
| Rai & Thakur, 2013 | Yes | Yes | Yes | No | NA | Yes | Yes | Yes | Yes | Yes | Yes |

5th November 2022

To
The Editor
BMJ Pediatrics Open,

Dear Editor,

We thank you for the opportunity to re-submit our manuscript titled "**A systematic review of early hearing detection and intervention (EHDI) programs for infants and young children in low and middle income countries in Asia**" with all the suggested corrections received during our initial submission (bmjpo-2022-001725). The PRISMA checklist for systematic reviews is filled and provided as enclosure (Enclosure 1).

The following were the suggestions provided and our response;

1. Justify excluding papers from 2022. Ideally extend your search

The search was expanded to include articles till 2022 and seven articles were included (2 India, 1 China, 1 Thailand, 1 Malaysia, 1 Nepal and 1 Bangladesh). Based on this inclusion, suitable changes have been made to the entire results section including text, tables and figures.

2. Supplementary Tables 1A and 1B need to be in the main paper

Supplementary Tables 1A (now Tables 1A-1E) and 1B (now Table 2) are included in the main manuscript

3. Table 1A would be better as 2 -5 separate tables: divided by country of origin.

Table 1A has been divided by country of origin (Tables 1A-1E)

4. Avoid use of % when describing your results - just state number of studies

All % are removed and only the numbers are retained

5. By having your tables in the main paper you should be able to shorten the text

We were unable to reduce the text significantly at this juncture as the data in tables and text are considerably exclusive. However, we are open to any specific comments received from reviewers to eliminate certain sections if required.

6. State the languages of the papers excluded and justify their inclusion.

All studies published in languages other than English were excluded as the authors are not competent with other languages. Based on this, eight Chinese language papers were excluded and this has been mentioned now in the PRISMA flow diagram.

Unlike several high income countries, EHDI programs are not mandated in many low and middle income countries (LMICs). In this context, we conducted a systematic review and gathered information on hearing screening programs mainly to identify different models of EHDI that were implemented in the context of Asian LMICs. This is one of the first systematic reviews that highlights the EHDI program models in the context of LMICs.

This review provides information on various screening protocols, tools, personnel, diagnostic tools, use of ICT, barriers and facilitators in different EHDI programs of LMICs. This study also highlights the validity and efficacy of these EHDI programs. We found that the screening tools and protocols used were similar to those used in high-income countries. However, no uniform protocols were followed within each country. Long term viability of EHDI programs was not known as there was limited information on impact outcomes such as cost-benefit.

Truly,

Vidya Ramkumar

Enclosure 1: PRISMA checklist for systematic reviews

| Section and Topic | Item # | Checklist item | Location where item is reported |
|-------------------------------|--------|--|---------------------------------|
| TITLE | | | |
| Title | 1 | Identify the report as a systematic review. | Yes |
| ABSTRACT | | | |
| Abstract | 2 | See the PRISMA 2020 for Abstracts checklist. | |
| INTRODUCTION | | | |
| Rationale | 3 | Describe the rationale for the review in the context of existing knowledge. | Yes |
| Objectives | 4 | Provide an explicit statement of the objective(s) or question(s) the review addresses. | Yes |
| METHODS | | | |
| Eligibility criteria | 5 | Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses. | Yes |
| Information sources | 6 | Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted. | Yes |
| Search strategy | 7 | Present the full search strategies for all databases, registers and websites, including any filters and limits used. | Yes |
| Selection process | 8 | Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process. | Yes |
| Data collection process | 9 | Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process. | Yes |
| Data items | 10a | List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect. | Yes |
| | 10b | List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information. | Yes |
| Study risk of bias assessment | 11 | Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process. | Yes |
| Effect measures | 12 | Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results. | Yes |
| Synthesis | 13a | Describe the processes used to decide which studies | Yes |

| Section and Topic | Item # | Checklist item | Location where item is reported |
|-------------------------------|--------|--|---------------------------------|
| methods | | were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)). | |
| | 13b | Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions. | Yes |
| | 13c | Describe any methods used to tabulate or visually display results of individual studies and syntheses. | Yes |
| | 13d | Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used. | Yes |
| | 13e | Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression). | NA |
| | 13f | Describe any sensitivity analyses conducted to assess robustness of the synthesized results. | NA |
| Reporting bias assessment | 14 | Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases). | Yes |
| Certainty assessment | 15 | Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome. | Yes |
| RESULTS | | | |
| Study selection | 16a | Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram. | Yes |
| | 16b | Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded. | NA |
| Study characteristics | 17 | Cite each included study and present its characteristics. | Yes |
| Risk of bias in studies | 18 | Present assessments of risk of bias for each included study. | Yes |
| Results of individual studies | 19 | For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots. | No |
| Results of syntheses | 20a | For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies. | Yes |
| | 20b | Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect. | Yes |
| | 20c | Present results of all investigations of possible causes of heterogeneity among study results. | NA |
| | 20d | Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results. | NA |

| Section and Topic | Item # | Checklist item | Location where item is reported |
|--|--------|--|--|
| Reporting biases | 21 | Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed. | No |
| Certainty of evidence | 22 | Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed. | No |
| DISCUSSION | | | |
| Discussion | 23a | Provide a general interpretation of the results in the context of other evidence. | Yes |
| | 23b | Discuss any limitations of the evidence included in the review. | Yes |
| | 23c | Discuss any limitations of the review processes used. | Yes |
| | 23d | Discuss implications of the results for practice, policy, and future research. | Yes |
| OTHER INFORMATION | | | |
| Registration and protocol | 24a | Provide registration information for the review, including register name and registration number, or state that the review was not registered. | Yes |
| | 24b | Indicate where the review protocol can be accessed, or state that a protocol was not prepared. | Yes |
| | 24c | Describe and explain any amendments to information provided at registration or in the protocol. | Yes |
| Support | 25 | Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review. | Yes |
| Competing interests | 26 | Declare any competing interests of review authors. | NA |
| Availability of data, code and other materials | 27 | Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review. | Yes. Can be accessed by contacting authors |

BMJ Paediatrics Open

A systematic review of early hearing detection and intervention (EHDI) programs for infants and young children in low and middle income countries in Asia

| | |
|-------------------------------|---|
| Journal: | <i>BMJ Paediatrics Open</i> |
| Manuscript ID | bmjpo-2022-001752.R1 |
| Article Type: | Original research |
| Date Submitted by the Author: | 25-Dec-2022 |
| Complete List of Authors: | Joshi B, Deepashree; Sri Ramachandra Institute of Higher Education and Research (Deemed to be University), Sri Ramachandra Faculty of Audiology and Speech Language Pathology ; Sri Ramachandra Institute of Higher Education and Research (Deemed to be University), Sri Ramachandra Faculty of Audiology and Speech Language Pathology Ramkumar, Vidya; Sri Ramachandra Institute of Higher Education and Research (Deemed to be University), Sri Ramachandra Faculty of Audiology and Speech Language Pathology Nair, Lekha; National Institute of Speech and Hearing, Department of Audiology and Speech Language Pathology Kuper, Hannah; London School of Hygiene and Tropical Medicine Faculty of Public Health and Policy, Department of Population Health |
| Keywords: | Deafness, Neonatology, Health services research, Audiology |
| | |

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1 **TITLE:** A systematic review of early hearing detection and intervention (EHDI) programs for infants and
2 young children in low and middle income countries in Asia
3

4 **AUTHORS:**

5
6
7 Deepashree Joshi B¹ (First author), Vidya Ramkumar¹ (Corresponding author), Lekha S Nair², Hannah
8 Kuper³
9

10
11 **AFFILIATIONS:**

- 12
13
14 1. Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India – 600116
15 2. National Institute of Speech and Hearing, Trivandrum, Kerala, India - 695017
16 3. London School of Hygiene and Tropical Medicine, London, United Kingdom - WC1E 7HT
17

18 **Corresponding author:**

19
20
21 Dr. Vidya Ramkumar,
22 Associate professor,
23 Intermediate Fellow, DBT/Wellcome trust India Alliance,
24 Sri Ramachandra Faculty of Audiology and Speech, Language Pathology
25 Sri Ramachandra Institute of Higher Education and Research
26 Chennai, Tamil Nadu, India – 600116
27 Email id: vidya.ramkumar@sriramachandra.edu.in
28
29
30
31
32
33
34
35
36
37

38 **WORD COUNT:** 4484 (Excluding title page, abstract and references)
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

KEY WORDS

1
2 Hearing Screening
3
4 Hearing Impairment
5
6 Children
7
8 Early Hearing Detection and Intervention
9
10 Screening programs
11
12 Pediatrics
13
14 New born
15
16 Infants
17
18 Low Middle Income Countries
19
20 Asia
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Confidential: For Review Only

Abbreviations

| | | |
|----|--------|--|
| 1 | | |
| 2 | EHDI | Early Hearing Detection and Intervention |
| 3 | | |
| 4 | LMIC | Low Middle Income Countries |
| 5 | | |
| 6 | LIC | Low Income Countries |
| 7 | | |
| 8 | MIC | Middle Income Countries |
| 9 | | |
| 10 | UMIC | Upper Middle Income Countries |
| 11 | | |
| 12 | HIC | High Income Countries |
| 13 | OAE | Oto Acoustic Emissions |
| 14 | AABR | Automated Auditory Brainstem Response |
| 15 | | |
| 16 | ABR | Auditory Brainstem Response |
| 17 | | |
| 18 | TEOAE | Transient Evoked Oto Acoustic Emissions |
| 19 | | |
| 20 | DPOAE | Distortion Product Oto Acoustic Emissions |
| 21 | PRISMA | Preferred Reporting Items for Systematic Reviews and Meta-Analyses |
| 22 | | |
| 23 | ICT | Information and Communication Technology |
| 24 | | |
| 25 | ASSR | Auditory Steady State Response |
| 26 | | |
| 27 | MeSH | Medical Subject Headings |
| 28 | | |
| 29 | WHO | World Health Organization |
| 30 | | |
| 31 | NHS | Newborn Hearing Screening |
| 32 | | |
| 33 | SNHL | Sensori Neural Hearing Loss |
| 34 | | |
| 35 | | |
| 36 | | |
| 37 | | |
| 38 | | |
| 39 | | |
| 40 | | |
| 41 | | |
| 42 | | |
| 43 | | |
| 44 | | |
| 45 | | |
| 46 | | |
| 47 | | |
| 48 | | |
| 49 | | |
| 50 | | |
| 51 | | |
| 52 | | |
| 53 | | |
| 54 | | |
| 55 | | |
| 56 | | |
| 57 | | |
| 58 | | |
| 59 | | |
| 60 | | |

ABSTRACT

Background: Early Hearing Detection and Intervention (EHDI) measures initiated in high income countries were attempted in low and middle income countries (L & MIC). However, information regarding the models of EHDI, context specific adaptations made to strategies, and outcomes are not known. **Aim:** The aim of this systematic review was to identify the various models of EHDI used in the Asian L&MICs in the published scientific literature, and to describe their efficacy and validity. **Method:** The studies were eligible if the program was from an Asian LICs and MICs, implemented for children below 6 years of age and published between 2010 - 2021. Google Scholar, Pubmed, Web of Science, Scopus, EBSCOHost, and EBSCO-CINAHL were used to find articles. Data were extracted from each selected article, and the risk of bias was assessed. The search results were summarised using the PRISMA flow diagram. For primary outcomes, narrative synthesis was used, and forest plots were generated for secondary outcomes. **Results:** In all, 82 studies were included and these studies were divided into two categories: newborn and infant screening programmes and screening programmes for older children. Predominantly, a two-stage objective OAE(DP/TE) or AABR screening, followed by a detailed auditory brainstem response to confirm the hearing loss, was used in newborn and infant screening programmes. Audiologists were the most frequent screening personnel. Screening of older children was mostly done by otolaryngologists, school instructors, and nurses. They performed a single stage pure tone audiometry screening followed by a detailed examination. **Conclusion:** The screening tools and protocols used were similar to those used in high-income countries (HICs). However, no uniform protocols were followed within each country. Long term viability of EHDI programs was not known as there was limited information on impact outcomes such as cost-benefit.

KEY MESSAGES

What is already known?

Early Hearing Detection and Intervention (EHDI) programs are mandated in several high income countries (HICs) for over two decades. These screening programs are based on guidelines and standards provided by JCIH (Joint Committee for Infant Hearing), AAA (American Audiology Association), NHSP England (Newborn Hearing Screening Program England), WHO (World Health Organization), European Consensus Statement on Neonatal Hearing Screening etc. Systematic reviews have documented screening protocols and program outcomes predominantly in the context of HICs.

What this study adds?

Unlike several HICs, EHDI programs are not mandated in many Low and Middle Income Countries (L&MICs). In this context, we conducted a systematic review and gathered information on hearing screening programs mainly to identify different models of EHDI that were implemented in the context of Asian LICs and MICs. This is the first known review that provides information on various screening protocols, tools, personnel, diagnostic tools, use of information and communication technology, barriers and facilitators in different EHDI programs of L&MICs.

How this study might affect research, practice or policy sections?

We found that the screening tools and protocols used were similar to those used in HICs, yet no uniform protocols were followed within each country. Long term viability of EHDI programs is not known in this context due to limited impact outcome based studies(eg:cost-benefit,rate of intervention etc.), hence future research should focus on these aspects. Further policy makers and program planners in these countries should build consensus to implement uniform country wise protocols suited to the context.

INTRODUCTION

Currently, 34 million children below 15 years are estimated to have hearing loss, with a higher prevalence in low and middle income countries (L& MICs)(2.4%) than in high income countries (HICs) (0.5%) [1]. Early Hearing Detection and Intervention (EHDI) for children with hearing loss is critical to maximize linguistic competence and literacy development. EHDI is a concept that emanated in the United States in the 1990s and is intended as an, at-birth hearing screening of newborns prior to hospital discharge. Infants who do not pass the screening are recommended for diagnostic evaluation and, when confirmed to have hearing loss, are enrolled in early intervention programs. Subsequently, Joint Committee of Infant Hearing (JCIH) (2007) in the US, recommended that all infants should be screened for hearing by 1 month of age, diagnosed by 3 months and intervened by 6 months of age [2]. It is practiced as a mandatory universal screening in the entire country.

The concept was subsequently adopted in UK and practiced as universal screening since 2006. Subsequently, several other high income countries (Australia, Canada to name a few) adopted this strategy. Alternative strategies for EHDI have been implemented in L & MICs, due to financial, human resource and infrastructural challenges [3]. These include high-risk based screening [4], screening during immunization [5], community based hearing screening by health workers [6,7] and school entry level screening [8,9]. Several of these programs have also integrated tele-practice to either improve coverage of screening or to provide better diagnostic follow-up [10,11]. However, there remains a lack of clarity on the range of strategies implemented in L&MICs, and which should be promoted.

The aim of this systematic review is to identify different models of EHDI that have been implemented in the context of Asian L&MICs in the published scientific literature, and describe evidence of their efficacy and validity.

METHOD

The protocol for this systematic review was registered in PROSPERO (Reg No: CRD42021240341)

Patient and Public Involvement statement:

This systematic review did not involve any subject/patient and public directly.

Inclusion criteria

All types of study designs were eligible for this review, including i) Cross-sectional ii) Cohort iii) Case-control iv) Randomized control trials v) Quasi-experimental and vi) field trials. Both qualitative and quantitative types of studies were included

1 The EHDI model is operationally defined for the purpose of this systematic review as programmes for
2 identification and referral of young children with hearing loss. Studies that described EHDI programs related
3 to triaging children suspected with hearing loss using methods such as objective or subjective screening,
4 parental questionnaire based screening, implemented in the context of Low Income Countries (LICs), Lower
5 Middle Income Countries (LMICs) and Upper Middle Income Countries (UMICs) including hospital,
6 community, school based or any other alternative approach were included.
7
8
9

10
11 Studies were eligible regardless of screening strategies (e.g. at birthing hospital/community/school), protocol
12 used (e.g. single stage/ two-stage), provider stakeholder (e.g. private/ public) involved, tools for screening
13 (e.g. checklist, OAE, AABR etc), or personnel involved in screening, diagnosis and intervention (e.g. nurse,
14 audiometrists, audiologist, ENT). We also included studies that explored evidence of validity (e.g.
15 sensitivity/specificity) and reported implementation barriers and facilitators to EHDI.
16
17
18
19

20
21 According to World Bank classification (2021), LICs, LMICs and UMICs (LICs and MICs) in Asian
22 continent (South East Asia, Central Asia and Western Asia/Middle East) were considered as eligible for the
23 review. In the LICs and MICs, 6 years and below was predominantly considered as the age band for 'early'
24 detection and intervention. Therefore, this review included studies describing EHDI among neonates, infants
25 and children below 6 years of age. Studies were eligible if they had been published from 2010-2022.
26
27
28
29

30 **Exclusion criteria**

31
32 We excluded studies that described hearing screening programs for individuals older than 6 years of age, or
33 for other disabilities not including hearing. In addition, studies from high income countries, studies
34 published in languages other than English, and studies published before the year 2010 were excluded.
35
36
37

38 **Search strategy**

39
40 Since EHDI is an interdisciplinary program often implemented by ENT/ Pediatrics/ neonatology/ audiology/
41 nursing, databases that captured articles from multiple disciplines was preferred. The primary databases used
42 for the search includes; PUBMED, Scopus, Web of science, EBSCOHost, EBSCO-CINAHL (humanities
43 and social sciences), and Google scholar. Hand searching was conducted for the International Journal of
44 Audiology (2015 to 2022) and bibliographies of the selected papers based on the eligibility criteria. Grey
45 literature search included ProQuest Dissertations & Theses Global (Interdisciplinary) and first 500 searches
46 for articles/ reports in Google search. We excluded social media articles, newspaper articles, editorials,
47 website information.
48
49
50
51
52
53

54
55 A search strategy for each of the above mentioned databases was designed using 2Dsearch online tool [12] .
56 The search strategy included MeSH terms and Boolean operators (Appendix 1). A pilot search was
57 conducted in each database to identify the keywords. Synonyms of the keywords were then identified and
58 included in the search strategy.
59
60

Screening for eligibility and quality

Title screening was conducted as per the inclusion and exclusion criteria using database search. The Rayyan software [13] was used to screen abstract and full texts. Screening was conducted by two reviewers (DJ, VR) and any discrepancies were discussed between the reviewers and decisions were made. Joanna Briggs Quality assessment tools specific to the research design was used to assess the quality of the articles.

PRISMA flowchart [14] was used to represent the search results.

Data extraction and synthesis:

A Google sheet was used for data extraction, which was undertaken by two authors (DJ and LN) and was verified by another author (VR).

Narrative synthesis of available data was conducted using textual approach to describe strategies adopted for EHDI including screening methods, service delivery points, use of information and communications technology (ICT), the target age groups of such programs, personnel involved in delivery of the program and reported barriers and facilitators of the program. JBI tool for critical appraisal [15] was used for quality assessment. The Synthesis Without Meta-analysis (SWiM) guideline was used for analysis of secondary outcomes [16]. If a country had at least three studies that reported data on children with confirmed hearing loss, then that country was included for estimation of prevalence per 1000 using forest plots.

The primary outcomes of interest were i) validity and efficacy of the screening programmes. We developed a checklist (Figure 2A & 2B) to assess the validity and efficacy using three criteria each. The items in the validity checklist included; i) the use of a *validated screening tool*, ii) the use of a *validated diagnostic tool*, whether the screening programme reported was in the iii) *design phase* (e.g. pilot/feasibility/validity/only reported coverage rate or referral rate or follow up rate) or *implementation phase* (e.g. scale programme). The efficacy was assessed if the study reported the i) evidence of early identification ii) evidence of early intervention ii) inclusion of an economic analysis.

The secondary outcome of interest was to estimate the incidence & prevalence outcomes of EHDI programs in the L&MICs Asian countries. For secondary outcomes analysis, in screening programs for newborns and infants, the prevalence of hearing loss in infants reported in each country was analyzed using the SWIM guidelines. Using a random effect model, Forest plots (Figure 3A-E) were constructed for each country based on two criteria: if more than five studies in a country reported prevalence outcomes, and if the number of children screened was more than one thousand.

RESULTS

1 Our electronic search yielded 1312 citations. Based on the inclusion/exclusion criteria and multiple levels of
2 screening by the two reviewers independently, a total of 82 studies qualified for the current review. The article
3 selection process is presented in the PRISMA flow chart (Figure 1). Sixty five (79%), reported on newborn
4 hearing screening, and only seventeen studies (21%) reported hearing screening among older children.
5 Predominantly studies were conducted in India (n=27) followed by Turkey (n=13), Iran (n=13), China (n=15),
6 Thailand (n=6), Malaysia (n=3), Nepal (n=1), Bangladesh (n=1), Iraq (n=1), Jordan (n=1), Tajikistan (n=1).
7 These studies included 75 cross sectional studies and 7 cohort studies. Results of quality appraisal using
8 appropriate JBI tool is provided in supplementary file 1.
9
10
11
12
13
14

15
16 ***Insert Figure 1: PRISMA flowchart representing the selection of article at each stage***
17

18 The screening programs identified in this review were grouped based on the age group of the children: 1)
19 screening programs for newborns and infants (0-3 years of age); screening programs for older children even
20 beyond 6 years of age.
21
22
23

24 Hearing screening programs for newborns and infants (below 2 years) included 65 studies. Most studies (49)
25 reported single-hospital programmes, whereas others (16 studies) reported multiple-center programmes. Of
26 these studies, 55 were undertaken in the private sector and 10 in the public sector. There were 17 studies of
27 hearing screening programmes for older children aged 3 to 17. Fifteen of these studies were school-based
28 hearing screenings, while two were community-based. Of these studies, 9 were undertaken in the private
29 sector and 8 in the public sector. Table 1A to E represent the summary of included studies describing hearing
30 screening programs for newborns and infants in each country.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1A: Hearing screening programs for newborns and infants in India (LMIC)

| Author and Year | Citation | Years of program | Population screened | Number screened | Screening protocol | Screening test used | Screening personnel | Diagnostic test |
|-----------------------------|----------|------------------|----------------------------|---|---|--|---|-----------------------------|
| Biswas et al., 2012 | [17] | 2 years | newborns | 490 | 1 stage | DPOAE | Not mentioned | Not mentioned |
| Paul et al., 2011 | [18] | 7 years | newborns | 10165 | 2 stage | OAE + OAE (not mentioned DP/TE) | Person with basic knowledge in computer with training on NHS. | Diagnostic ABR |
| Mishra et al., 2013 | [19] | 3 years | 0-2 years | 1101 | <6 months of age- 5 stage; 6m to 1yr-4 stage ; 1 yr to 2 yrs -3 stage | DPOAE | Not mentioned | Diagnostic ABR |
| Ramesh et al., 2012 | [20] | 2 years | newborns | 425 | 1 stage | Calibrated noise maker based BOA | Trained health workers (30 hours of training) | Diagnostic ABR, OAE & BOA |
| Rai & Takur et al., 2013 | [21] | 1 year | newborns | 500 | 3 stage | TEOAE +TEOAE +TEOAE | ENT | Diagnostic ABR |
| Kumar et al., 2015 | [22] | 1 year 8 months | High risk < 2 years of age | 500 | 2 stage | TEOAE+AABR | Audiologist | Not mentioned |
| Gupta et al., 2015* | [23] | 1 year | newborns | 2265 | 2 stage | AABR + AABR | Single specialist staff | Not mentioned |
| Vignesh et al., 2015 * | [24] | 1.5 years | newborns | 1405 | 2 stage | TEOAE+AABR | Not mentioned | Diagnostic ABR |
| Vishwakarma et al., 2015 | [25] | 1 year 8 months | newborns | Wellbabies : 2000 high risk :1020 | 3 stage | TEOAE+TEOAE + AABR | Nurse, Resident doctor/ certified audiologist | Diagnostic ABR |
| Paul et al., 2016 | [26] | 11 years | newborns | Wellbabies : 84774 High risk: 16,914 | 2 stage | OAE+ OAE (Not mentioned DP/TE) | Person with basic training in hearing screening | Diagnostic ABR |
| Sharma et al., 2018 | [27] | 3 years | newborns | 2534 | 2 stage | DPOAE | Not mentioned | Diagnostic ABR |
| Kumar et al., 2016* | [28] | 2 years | newborns | 1537 | 2 stage | TEOAE+TEOAE + AABR | Not mentioned | Not mentioned |
| Sachdeva & Sao et al., 2017 | [29] | 10 months | newborns | 2254 | 2 stage | (HRR + BOA + DPOAE) + DPOAE | Not mentioned | Confirmatory Diagnostic ABR |
| Kumar et al., 2017 | [30] | No info | newborns | 600 | 2 stage | TEOAE+DPOAE | Not mentioned | Not mentioned |
| Swain et al., 2017 | [31] | 1.5 years | newborns | 410 | 2 stage | DPOAE + DPOAE | Not mentioned | Diagnostic ABR |
| Bhat et al., 2018 | [32] | 1 year | High risk newborns | 195 | 1 stage | TEOAE | Not mentioned | Diagnostic ABR |
| Bishnoi et al., 2018 | [33] | No info | newborns | 2000 | 2 stage | (OAE & TYMP) + OAE (not mentioned DP/TE) | Not mentioned | Diagnostic ABR |
| Parab et al., 2018 * | [34] | 3 years | newborns | 8192 | 2 stage | TEOAE + TEOAE | Audiologist | Diagnostic ABR |

| | | | | | | | | |
|--------------------|------|---------|----------|-------|---------|-------------------------------|---------------|----------------|
| Jacob et al.,2020 | [35] | 2 years | newborns | 773 | 2 stage | TEOAE +TEOAE | Not mentioned | Diagnostic ABR |
| Nishad et al.,2020 | [36] | 1 year | newborns | 1000 | 2 stage | OAE+OAE (not mentioned DP/TE) | Not mentioned | Diagnostic ABR |
| Sija et al., 2022 | [37] | 4 years | Newborns | 16265 | 2 stage | DPOAE +DPOAE | Trained nurse | Diagnostic ABR |

Table 1B: Hearing Screening programs for newborns and infants in China (UMIC)

| Author and Year | Citation | Years of program | Population screened | Number screened | Screening protocol | Screening test used | Screening personnel | Diagnostic test |
|---------------------|----------|------------------|---------------------|-----------------|-----------------------------|--|-----------------------------|--|
| Zhang et al., 2012 | [38] | 1.5 years | newborns | 10043 | 2 stage + genetic screening | TEOAE+ (TEOAE& AABR) | Nurse | Not mentioned |
| Tobe et al.,2013 | [39] | 2 years | newborns | Not mentioned | 2 stage | OAE+AABR (not mentioned DP/TE) | Trained personnel - no info | Not mentioned |
| Chen et al.,2012 | [40] | 2 years | newborns | 11568 | 2 stage | TEOAE | Audiologist | Diagnostic ABR, TFT, Impedance, ASSR at hospital |
| Shang et al.,2016 | [41] | 6 months | newborns | 1064 | 2 stage | 1st protocol: TEOAE + TEOAE 2nd protocol: (TEOAE & ABR screen) + TEOAE | Not mentioned | Diagnostic ABR |
| Wenjin et al., 2018 | [42] | 2 years | newborns | 19098 | 2 stage | Well babies : DPOAE + ABR screening High risk babies: (DPOAE & ABR screening) + (DPOAE & ABR screening) | Nurse | Otосcopy, Diagnostic ABR at 30dBHL, Tympanometry; DPOAEs |
| Wang et al., 2019 | [43] | 5 years | newborns | 55,977 | 2 stage | OAE+AABR (Non mentioned DP/TE) | Nurse | Comprehensive diagnostic audiometry around three months of age |
| Dai et al.,2019 | [44] | 1 year | newborns | 180469 | 2 stage + genetic screening | TEOAE + (TEOAE & AABR) | Not mentioned | Diagnostic ABR, ASSR, DPOAE, Immitance |
| Zeng et al., 2020 | [45] | 1 year | newborns | 4205 | 2 stage + genetic screening | OAE+AABR screening (Not mentioned DP/TE) | Not mentioned | No |
| Wen et al., 2020 * | [46] | 2 years | newborns | 467980 | 2 stage | OAE + (OAE & AABR) (not mentioned DP/TE) | Not mentioned | Not mentioned |
| Guo et al., 2020 | [47] | 2 years 4 months | infants > 3 months | 2,87,430 | 2 stage + genetic | OAE +AABR (Non mentioned DP/TE) | Not mentioned | Diagnostic ABR |
| Guomei et al.,2022 | [48] | 9 months | Newborns | 2174 | 2 stage + genetic | OAE + OAE (Not mentioned DP/TE) | Not mentioned | Diagnostic ABR |

Table 1C: Hearing Screening Programs for newborns and infants in other Asian countries

| Author and Year | Citation | Country | Years of program | Population screened | Number screened | Screening protocol | Screening test used | Screening personnel | Diagnostic test |
|-----------------------------|----------|-------------------|------------------|---------------------|-----------------|--------------------|--|--|-----------------------------------|
| Ahmad et al.,2011 | [49] | Malaysia (MIC) | 5 years | newborns | 16000 | 3 stage | DPOAE +DPOAE + DPOAE | Technician, staff nurse, ward attendants | Diagnostic ABR |
| Wong et al.,2020 | [50] | Malaysia (UMIC) | 2 years | newborns | 28432 | 1 and 2 stage | 1 stage AABR 2 stage - DPOAE + AABR | Nurses | Diagnostic ABR |
| Tungvachira kul et al.,2011 | [51] | Thailand (UMIC) | 1 year 11 months | newborns | 4043 | 2 stage | OAE+ OAE (Not mentioned DP/TE) | Not mentioned | ASSR |
| Poonual et al.,2016 | [52] | Thailand (UMIC) | 1 year 7 months | newborns | 3120 | 2 stage | Automated TEOAE + Conventional TEOAE | Not mentioned | Diagnostic ABR |
| Poonual et al.,2017 | [53] | Thailand (UMIC) | Not mentioned | newborns | 3120 | 3 stage | COBRA HRR tool + TEOAE + AABR | Not mentioned | Not mentioned |
| Poonual et al., 2017b | [54] | Thailand (UMIC) | 1 year | newborns | 3120 | 2 stage | TEOAE+ AABR | Not mentioned | ABR at 3 and 8 months |
| Pitathawat hai et al.,2019 | [55] | Thailand (UMIC) | 1 year 7 months | newborns | 6140 | 2 stage | TEOAE+TEOAE | Nurses | Not mentioned |
| Ray et al.,2021 | [56] | Nepal (LMIC) | 2 years | newborns | 540 | 2 stage | OAE+OAE (Not mentioned DP/TE) | Not mentioned | Diagnostic OAE and Diagnostic ABR |
| Mazlan et al.,2022 | [57] | Malaysia (UMIC) | 10 years | newborns | 50633 | 2 stage | TEOAE +AABR | Trained nurses and medical technologists | Diagnostic ABR |
| Shameem et al., 2022 | [58] | Bangladesh (LMIC) | 2 years | High risk newborns | 426 | 2 stage | TEOAE + TEOAE | Not mentioned | Diagnostic ABR |
| Khaimook et al.,2022 | [59] | Thailand (UMIC) | 6 months | newborns | 1696 | 2 stage | TEOAE + TEOAE | Trained Nurse & audiologist | Diagnostic ABR + Tympanometry |

Table 1D: Hearing screening programs for newborns and infants in Turkey (UMIC)

| Author and Year | Citation | Years of program | Population screened | Number screened | Screening protocol | Screening test used | Screening personnel | Diagnostic test |
|----------------------------|----------|------------------|---------------------|-----------------|--------------------|---------------------|-----------------------------|--|
| Tasci et al.,2010 | [60] | 14 months | newborns | 16,975 | 3 steps | TEOAE+ TEOAE+ ABR | Audiology technician | Diagnostic ABR |
| Sennaroglu & Akmesel, 2011 | [61] | 1 year | newborns | 1840 | 2 stage | TEOAE | Audiologist or audiometrist | Diagnostic ABR; |
| Ulusoy et al.,2014 | [62] | 3 years | newborns | 11575 | 3 stage | TEOAE+ AABR | 2 audiometrists and 1 nurse | Diagnostic ABR, the level three center |
| Kemaloğlu et al., 2016 | [63] | 10 years | newborns | 19436 (I/P) | 3 stage | TEOAE+ TEOAE+ | Audiology technicians and | Diagnostic ABR |

| | | | | | | | | |
|-----------------------|------|-----------|----------|---------------------------|---------|--|--------------------|---|
| | | | | 2083 (O/P) | | (TEOAE & AABR) | audiology students | |
| Yorulmaz et al., 2017 | [64] | 5 years | newborns | 13693 | 3 stage | TEOAE+TEOAE+AABR | Audiometrist | Diagnostic ABR, Tympanometry, Acoustic reflexes, ASSR |
| Celik et al., 2016 | [65] | 6 years | newborns | 142128 | 2 stage | TEOAE (twice same day)+ TEOAE | Not mentioned | Diagnostic ABR |
| Ozturk et al., 2017 | [66] | 2 years | newborns | 7502 | 3 stage | Wellbabies: DPOAE+DPOAE+ABR screening Highrisk babies: Direct ABR | Audiologist | Diagnostic ABR |
| Hamdi, 2018 | [67] | 2 years | newborns | 1808 | 3 stage | TEOAE+TEOAE+ABR screening | Nurses (Trained) | Diagnostic ABR |
| Yücel et al., 2019 | [68] | 2 years | newborns | 786 syrian & 7230 turkish | 3 stage | (TEOAE & Tymp) + TEOAE + ABR | Not mentioned | Detailed testing |
| Arslan et al., 2013 | [69] | 8 months | newborns | 2229 | 2 stage | TEOAE+ TEOAE | Nurse | Diagnostic ABR |
| Çikrikçi et al., 2020 | [70] | 1.5 years | newborns | 702 turkish 172 syrian | 2 stage | AABR + AABR | Not mentioned | Diagnostic ABR |

Table 1E: Hearing screening programs for newborns and infants in Iran (LMIC)

| Author and Year | Citation | Years of program | Population screened | Number screened | Screening protocol | Screening test used | Screening personnel | Diagnostic test |
|-------------------------------|----------|------------------|---------------------|-----------------|--------------------|--|--|-----------------------------------|
| Arjmandi et al., 2012 | [71] | 1 year | newborns | 1232 | 2 stage | TEOAE+TEOAE | Not mentioned | Diagnostic ABR |
| Islami et al., 2013 | [72] | 1.5 years | newborns | 7250 | 2 stage | TEOAE+TEOAE | Audiologists | Diagnostic ABR |
| Firoozbakht et al., 2014 | [73] | 8 years | newborns | 33,50,995 | 2 stage | TEOAE+AABR | audiologists, nurses, midwives and trained health technicians. | Comprehensive test |
| Zahed et al., 2014* | [74] | 8 years | newborns | 40930 | 2 stage | TEOAE+ABR | Audiologists | ABR/ASSR & immittance audiometry, |
| Farhat et al., 2014 | [75] | 2 years | newborns | 8987 | 2 stage | TEOAE+TEOAE | Not mentioned | ASSR |
| Haghshenas et al., 2014 | [76] | 2 years | newborns | 15,165 | 3 stage | OAE + OAE + (OAE & AABR) (Not mentioned DP/TE) | Audiologist | ABR screening |
| Baradaranfar et al., 2014 | [77] | 1 year | newborns | 514 | 2 stage | TEOAE+TEOAE | Not mentioned | Diagnostic ABR |
| Azizi et al., 2016 | [78] | 1.5 years | newborns | 3818 | 2 stage | TEOAE+TEOAE | not mentioned | ABR, |
| Tajik & Ahmadpour-Kacho, 2016 | [79] | 4 years | newborns | 3362 | 2 stage | TEOAE + (TEOAE & ABR) | Not mentioned | Not mentioned |
| Saki et al., 2017 | [80] | 3 years | newborns | 92,521 | 2 stage | 1st & 2nd: TEOAE + AABR | Audiologists | Diagnostic OAE and ABR |
| Rahimi et al., 2018 | [81] | 5 years | newborns | 4729 | 3 stage | TEOAE + TEOAE + AABR | Audiologist | Diagnostic ABR |

Table 2 : Hearing screening programs for older children

| Author and year | Citation | Country | Years of Program | Age of screening (years) | Number screened | Screening protocol | Screening test used | Pass/fail criteria | Screening personnel | Diagnostic test | Diagnostic person |
|----------------------|----------|---------|------------------|--------------------------|-----------------|--------------------|---|---|--|--|---------------------------|
| Tuli et al.,2012 | [82] | India | 2 years | 5 to 16 | 111 | 1 stage | Case history, Audiological & ENT evaluation, Awareness &SIFTER | Not mentioned | Not mentioned | ENT & PTA & Diagnostic ABR | Audiologist |
| Chadha et al., 2013 | [83] | India | 3 years | 5 to 12 | 15718 | 1 stage | Otoscopy, Ten question screening index for disabilities" in English and Hindi | Positive history of hearing or speech defects, A positive finding on examination. | Proforma-parents, Otoscopy - otolaryngologists | Not mentioned | Not mentioned |
| Ramkumar et al.,2018 | [84] | India | 2 years | Birth to 5 years | 1335 | 2 stage | DPOAE +DPOAE | >SNR 3 dB | Trained Village Health Worker | Tele-Diagnostic ABR | Audiologist |
| Ramkumar et al.,2019 | [85] | India | 2 years | Birth to 5 years | 2815 | 2 stage | DPOAE + DPOAE | >SNR 3 dB | Trained Village Health Worker | Diagnostic ABR – in person and Tele-diagnostic ABR | Audiologist |
| Verma et al.,2022 | [86] | India | 6 months | 6 to 17 years | 597 | 1 stage | Tuning fork test | Not mentioned | Not mentioned | PTA and Tympanometry | Audiologist |
| Shekhar et al., 2020 | [87] | India | Not mentioned | 5 to 14 | 474 | 1 stage | PTA | Not mentioned | ENT specialist | ENT examination | ENT specialist |
| Lu et al.,2011 | [88] | China | 1 year | 3 to 6 | 21427 | 1 stage | PTA | 1, 2 and 4KHz > 20dB | Screening person with training (training program with certificate) | PTA (5 to 6 years) VRA or Play PTA (3 to 4 years) | Not mentioned |
| Chen et al.,2013 | [89] | China | 1 year 5 months | 3 to 6 | 28546 | 1 stage | TEOAE | >SNR 3 dB | School nurses & doctors 2 hours of training | Comprehensive test | Not mentioned Audiologist |
| Wu et al.,2014 | [90] | China | Not mentioned | 3 to 6 | 6288 | 1 stage | Software based new PTA | >30dBHL at 1,2,4KHz | Preschool teachers - minimally trained | Not mentioned | Not mentioned |
| Kam et al.,2014 | [91] | China | Not mentioned | 3 to 7 | 6231 | 1 stage | Automated PTA | >30dBHL at 1,2 and 4KHz | Automatic test - Nurses with 2 hours training as facilitator | Tympanometry, DPOAE & PTA (0.25 to 8KHz) | Not mentioned |

| | | | | | | | | | | | | |
|----|---------------------------|------|-------------------|---------------|-----------------|-------|---------------|---|--|---|---|----------------|
| 1 | Tokgöz-Yılmaz et al.,2013 | [92] | Turkey | 3 years | 3 to 5 | 239 | 1 stage | PTA | Not mentioned | Audiologist and SLP | ENT examination | ENT specialist |
| 2 | | | | | | | | | | | | |
| 3 | Kaplam et al.,2020 | [93] | Turkey | 1 year | 69 to 84 months | 23664 | 2 stage | PTA, Ten questionnaire | 500, 1000, 2000 and 4000Hz > 20dB Ten question - Refer in 1 question | Certified nurses, midwives, health officers or audiometrists, | ENT examination | ENT specialist |
| 4 | | | | | | | | | | | | |
| 5 | | | | | | | | | | | | |
| 6 | | | | | | | | | | | | |
| 7 | | | | | | | | | | | | |
| 8 | | | | | | | | | | | | |
| 9 | | | | | | | | | | | | |
| 10 | | | | | | | | | | | | |
| 11 | TarviEslami et al.,2017 | [94] | Iran | 1 year | 6 to 7 | 2237 | Not mentioned | PTA | Not mentioned | Not mentioned | PTA, Weber, Rinne test | Not mentioned |
| 12 | | | | | | | | | | | | |
| 13 | Jalali et al.,2020 | [95] | Iran | 4 months | 6 to 13 | 2019 | 1 stage | PTA | 0.5KHz to 4KHz >15dBHL | Not mentioned | ENT examination & comprehensive audiological examination | Not mentioned |
| 14 | | | | | | | | | | | | |
| 15 | | | | | | | | | | | | |
| 16 | | | | | | | | | | | | |
| 17 | | | | | | | | | | | | |
| 18 | | | | | | | | | | | | |
| 19 | | | | | | | | | | | | |
| 20 | | | | | | | | | | | | |
| 21 | Pilka et al.,2016 | [8] | Tajikistan (LMIC) | Not mentioned | 6 to 8 | 143 | 1 stage | Questionnaire, PTA using SZOK telemed model | PTA module (500 to 8KHz) >25dB at one frequency, | Medical doctors Other specialists | Detailed PTA | Audiologists |
| 22 | | | | | | | | | | | | |
| 23 | | | | | | | | | | | | |
| 24 | | | | | | | | | | | | |
| 25 | | | | | | | | | | | | |
| 26 | | | | | | | | | | | | |
| 27 | Alaqrabawi et al.,2016 | [96] | Jordan (UMIC) | 4 years | 5 to 15 | 1649 | 1 stage | PTA | 500Hz, 1KHz, 2KHz & 4KHz > 25dB | Not mentioned | Audiometry Otoscopy Tympanometry | Audiologists |
| 28 | | | | | | | | | | | | |
| 29 | | | | | | | | | | | | |
| 30 | | | | | | | | | | | | |
| 31 | | | | | | | | | | | | |
| 32 | Al-Obeidy et al.,2019 | [97] | Iraq (UMIC) | 1 year | 6 | 425 | 1 stage | HR Questionnaire | Not mentioned | Not mentioned | ENT examination, TFT (Weber, Rinne and Absolute bone conduction). HRR children: PTA | Not mentioned |
| 33 | | | | | | | | | | | | |
| 34 | | | | | | | | | | | | |
| 35 | | | | | | | | | | | | |
| 36 | | | | | | | | | | | | |
| 37 | | | | | | | | | | | | |
| 38 | | | | | | | | | | | | |
| 39 | | | | | | | | | | | | |
| 40 | | | | | | | | | | | | |
| 41 | | | | | | | | | | | | |
| 42 | | | | | | | | | | | | |
| 43 | | | | | | | | | | | | |
| 44 | | | | | | | | | | | | |
| 45 | | | | | | | | | | | | |
| 46 | | | | | | | | | | | | |
| 47 | | | | | | | | | | | | |
| 48 | | | | | | | | | | | | |
| 49 | | | | | | | | | | | | |
| 50 | | | | | | | | | | | | |
| 51 | | | | | | | | | | | | |
| 52 | | | | | | | | | | | | |
| 53 | | | | | | | | | | | | |
| 54 | | | | | | | | | | | | |
| 55 | | | | | | | | | | | | |
| 56 | | | | | | | | | | | | |
| 57 | | | | | | | | | | | | |
| 58 | | | | | | | | | | | | |
| 59 | | | | | | | | | | | | |
| 60 | | | | | | | | | | | | |

Abbreviations: PTA: Pure Tone Audiometry; ABR-Auditory Brainstem Response; DPOAE-Distortion Product OtoAcoustic Emissions; TEOAE-Transient Evoked Oto Acoustic Emissions; TFT-Tuning Fork Test; HRR-High Risk Register; SNR-Signal to Noise Ratio; SIFTER: Screening Identification For Targeting Educational Risk; Tympanometry; UMIC: Upper Middle Income Country; LMIC: Lower Middle Income Country

Screening protocol and tests:

Newborn and infant hearing screening:

Two-stage hearing screening protocols were employed most frequently for newborn and infant hearing screening (n=47), followed by three-stage protocols (n=13), and one-stage protocols (n=4). One study reported employing a 5-step hearing screening protocol.

Sixteen studies that reported a two-stage hearing screening protocol, employed otoacoustic emission (OAE) (TE/DP-OAE) or Automated Auditory Brainstem Response (AABR) as screening tests (individually or combined in either stage [22,24,32,42-47,50,53,57,73,74,79]). Other twenty five studies used only OAEs (DP/TE) [19,26,34-37,40,51,55,56,58,59,61,65,69,71,72,78] or AABR screening [23,70] for testing in both stages. Those studies that reported the use of AABR in the initial stage of screening either employed AABR solely for both stages [23] or a combination of AABR and OAE to screen only high-risk newborns [41,42]. Four studies from China used 2 stage screening coupled with genetic hearing screening [43-45,47,48].

When a three-stage protocol was used, generally the first two stages included OAE (DP/TE) screening followed by AABR/ABR screening [25,60,62-64,66,67,76,81] or included OAE(DP/TE) for all three stages [21,49]. Only one study reported combining tympanometry and TEOAE in the initial stage of its three-stage screening protocol [68]. Studies from Turkey (n=7) reported three-stage screening protocol [60,62-64,66-68].

Screening for older children

Fourteen studies for older children employed a single stage screening protocol [8,82,83,87,88,90-92,95-97] with three employing a two stage protocol [85,3]. Ten studies reported using subjective hearing screening tests, two studies used questionnaire or otoscopy for screening [83,97] and another three studies used TEOAE [84,85]. Pure tone audiometry was the most commonly used subjective test for screening older children [87,88,92,94-96]; Two studies reported the use of automated software based PTA [90,91]. Pure tone audiometry was combined with questionnaires [8,93] or otoscopy [83,97]. Only one study reported the use of TEOAE screening [89].

Pass/ refer criteria

In several programs for newborn and infant screening, screening results were based on data generated from the screening instrument automatically. The pass criteria for DP/TEOAE was between 3 and 6 dB SNR [18,21,25,30,32,37,40,42,47,49,55,59,63,65,78] and for AABR it varied between 30 dB nHL, 35 dB nHL and 40 dB nHL [41,42,62,64,76]. Predominantly, refer results in one ear was considered for follow-up screening.

1 For screening older children, the pass criteria for pure tone audiometry ranged from 15dB HL to 30dB HL.
2 All studies used the four frequencies 0.5KHz to 4KHz for pure tone testing. In questionnaire-based studies,
3 failing one item or a family history of hearing loss were the referral criteria [83,87].
4
5

6 **Screening personnel:**

7
8
9 Audiologists were the primary screening personnel in many newborn and infant programs
10 [22,25,34,39,40,61,66,72,74,76,80,81]; followed by nurses [25,37,42,43,49,50,55,57,59,62,67,69,73]. In five
11 studies, the training provided for nurses to perform hearing screening was also briefly mentioned
12 [55,57,67,69,73]. including some certifications [62]. Other than nurses, some studies reported audiometrists
13 [61,62,64] and audiologist technicians [60] as personnel involved in screening. Other non-specialists that
14 were engaged in hearing screening were technicians [49], ward attendants [49], trained health workers [20,73]
15 social workers [39] and midwives [18,26,73]. In a few programmes, otolaryngologists [21] performed the
16 hearing screening. 29 out of 59 studies did not provide any information regarding the screening individual.
17
18
19
20
21
22
23

24 Screening for older children was conducted by otorhinolaryngologists [8,83,87] audiologists [92], and
25 audiometrists [93]. Other non-specialists involved in the hearing screening included trained nurses/midwives
26 [40,91,93], trained village health workers or volunteers [84,85] and school teachers with training [90].
27
28
29

30 Studies have reported a variety of training programmes. They included hearing screening certification [83,93];
31 2 hours of TEOAE training [40]; TEOAE training and tele-diagnostic testing facilitation [85]; and minimal
32 training/2 hours of training for facilitating automated PTA [90,91].
33
34
35

36 **Confirmation of hearing loss:**

37
38
39 Diagnostic Auditory Brainstem Response (ABR) was the only testing carried out to confirm the hearing loss
40 in studies in newborns and infants [19,21,25,27,29,31,33,35-37,47,57,58]. Comprehensive test battery
41 including the diagnostic BERA, OAE, and tympanometry was mentioned only in eleven studies [42,64,73].
42 Four studies also reported the inclusion of the Auditory Steady State Response (ASSR) in the test battery
43 [64,74].
44
45
46
47

48 Two programs utilized solely ASSR [51,75] and studies also used ABR screening at 30 dB nHL [42] or 35
49 dB nHL [76] for hearing loss diagnosis.
50
51
52

53 However, 11 of the 65 programs made no mention of the diagnostic confirmatory test used for confirmation
54 of hearing loss. More than half of the studies (n=37), reported that the diagnostic confirmatory test was
55 performed at the same hospital where screening was conducted. In another eighteen studies children were
56 referred to more specialist or tertiary care facilities for diagnostic confirmatory tests. The diagnostic site was
57 not mentioned or could not be inferred in 10 studies.
58
59
60

1 In studies reporting screening for older children, a test battery approach was used in 3 studies where they
2 included PTA with tympanometry and DPOAE [91] or PTA with otoscopy and tympanometry [96] or PTA
3 and detailed ABR [82]. Two studies reported the use of comprehensive test battery, but did not mention the
4 tests included [40].
5
6

7
8 Puretone audiometry (PTA) was frequently included in the diagnostic test battery [86,91,96], but in three
9 studies PTA was the only diagnostic test used [8,94,95]. Of the studies that reported the use of PTA for
10 diagnosis, only four studies [92,94,95,96] mentioned information related to bone conduction testing. . Apart
11 from these studies, ENT examination was included in five studies [87,92,93,95,97]. The diagnostic testing
12 sites included a hospital [95], a school [87], a speech and hearing centre [91], and a telemedicine platform
13 [8,85].
14
15
16
17

18 **Utilization of ICT**

19
20
21
22 In studies related to newborn and infant hearing screening, three programs reported the use of ICT for storing
23 and forwarding results [34], database management [39,57], and sending reminders for follow-up screening.
24
25

26
27 In studies reporting screening of older children, five studies reported using telepractice for screening,
28 diagnosis, or both. Tele-diagnostic ABR [84,85] was reported in India. use of m-health-based automated
29 hearing screening was reported in China by Wu et al. (2013) and Kam et al. (2014) a tele- sensory screening
30 platform including hearing screening (SZOK paradigm) in Tajikistan, where both screening and diagnosis
31 were carried out via telemedicine [8].
32
33
34

35 **Validity and efficacy of the screening programs:**

36
37
38
39 Validity of screening programs as reported in the studies was evaluated based on three criteria: use of a
40 validated screening tool, use of a validated diagnostic tool, whether the program was in design phase or in
41 implementation phase.
42
43
44

45
46 Among the studies that reported newborn and infant hearing screening, 48 studies fulfilled all 3 criteria of the
47 validity tool; Eleven studies fulfilled 2 out of 3 criteria; Six studies fulfilled 1 out of 3 criteria (Figure 2A).
48 Validated screening tool was used by sixty three studies and fifty four studies used a validated diagnostic tool.
49 As per the criteria we used, fifty five studies could be classified to be in the implementation phase and ten
50 studies were in design phase.
51
52
53

54
55 Economic analysis, frequency of identification and intervention were the 3 criteria included to assess efficacy.
56 Only two studies fulfilled all the three efficacy criteria, seventeen studies fulfilled two out of the three criteria,
57 thirty seven studies fulfilled only one of the three criteria, whereas remaining nine studies did not fulfil any of
58 the criteria. Fifty one studies only reported the frequency of identification, whereas fourteen reported both the
59
60

frequency of identification and intervention. Twelve percent of the studies did not mention either of these outcomes. Economic analysis was very limited (n=3) and were reported majorly in public programs.

Among the studies that reported screening programs for older children, ten studies fulfilled all the three criteria, three studies fulfilled two out of three criteria, three studies fulfilled one out of three criteria. Only one study did not meet any of the criteria [83] a questionnaire and an otoscopic examination to estimate the incidence of conductive hearing loss in older children.

With respect to efficacy, it was observed that none of the studies among older children fulfilled all the three criteria. Only five studies fulfilled two out of three criteria whereas the remaining twelve studies fulfilled only one criterion.

Fourteen studies have reported frequency of identification, but only five studies have reported the frequency of intervention (e.g. medical intervention for conductive pathology). The intervention related screening programs were reported from India, China and Turkey. The economic analysis was only reported in two studies [84,91]. Except for the economic analysis, only two of the 17 studies fulfilled all validity and efficacy criteria [85,88].

Prevalence of hearing loss

Across 48 studies, the mean prevalence of hearing loss among newborns and infants was 5/1000 in India, 2/1000 in China, 2/1000 in other Southeast Asian nations (Thailand, Malaysia and Nepal), 2/1000 in Turkey, and 4/1000 in Iran. Figure 3 (A to E) shows the forest plots for prevalence of each country.

In screening programs for older children, 11 studies reported number of cases with hearing loss including conductive and sensori neural hearing losses. However, in four studies [83,87,89,93] the specific audiological tests conducted to diagnose was not mentioned, and in seven studies [88,92,94-97] details of diagnostic audiometry was provided. In this age group, the percentage of conductive hearing loss reported was higher compared to sensori neural hearing loss across all the studies. In two studies, the type of loss was not differentiated [8,83]. The percentage of children identified with a certain type of hearing loss was calculated based on the information on number of children s diagnosed was provided in each of the studies. The study outcomes are reported in Table 3.

Table 3: Secondary outcomes: Studies reporting number of cases identified with conductive/sensorineural hearing loss in older children in each country

| Country | Author and year | Number screened | Number of CDHL identified | % of CDHL | Number of SNHL identified | % of SNHL | Overall number of HL identified | % of HL | LB (CI: 95%) | UB (CI: 95%) |
|---------|--------------------|-----------------|---------------------------|-----------|---------------------------|-----------|---------------------------------|---------|--------------|--------------|
| India | Chadha et al.,2013 | 15718 | NA | NA | NA | NA | 1578 | 10.30% | 9.57% | 10.52% |
| | Shekhar et al., | 474 | 146 | 30.80% | 1 | 0.21% | 147 | 31.01% | 26.87% | 35.39% |

| | 2020 | | | | | | | | | |
|-------------------|---------------------------|-------|-----|--------|----|-------|-----|--------|--------|--------|
| | Tokgöz-Yılmaz et al.,2013 | 239 | 25 | 10.46% | 1 | 0.42% | 26 | 10.88% | 7.23% | 15.53% |
| Turkey | Kaplama et al.,2020 | 23664 | 186 | 0.79% | 89 | 0.37% | 275 | 1.16% | 1.03% | 1.31% |
| | TarvijEslami et al.,2017 | 2284 | 28 | 1.23% | 8 | 0.35% | 36 | 1.58% | 1.11% | 2.18% |
| Iran | Jalali et al.,2020 | 2019 | 19 | 0.94% | 8 | 0.39% | 27 | 1.33% | 0.88% | 1.94% |
| Tajikistan | Pilka et al.,2016 | 143 | NA | NA | NA | NA | 34 | 23.70% | 17.06% | 31.61% |
| Jordan | Alaqrabawi et al.,2016 | 1649 | 54 | 3.27% | 36 | 2.18% | 90 | 5.45% | 4.41% | 6.61% |
| Iraq | Al-Obeidy et al.,2019 | 425 | 28 | 6.59% | 2 | 0.47% | 30 | 7.06% | 4.81% | 9.92% |
| | Lu et al.,2011 | 21547 | 285 | 1.32% | 16 | 0.07% | 301 | 1.39% | 1.24% | 1.56% |
| China | Chen et al 2012 | 28546 | 344 | 1.21% | 22 | 0.08% | 366 | 1.29% | 1.15% | 1.42% |

Abbreviations: CDHL: Conductive Hearing Loss; SNHL: Sensori Neural Hearing Loss; HL: Hearing Loss; LB: Lower Bound; UB: Upper Bound

Barriers and facilitators:

Barriers:

Loss to follow-up for second screening and diagnostics [18,25,29,35-37,42,55,59,62,66,72,73] was reported as a major challenge. Loss to follow up was linked to parental rejection for diagnosis [23,26,59], poor tracking system [42,73], financial burden of parents, low socioeconomic status [70] and travel distance to testing distance. Other major challenges highlighted in relation to outcomes included limited coverage [30,35], and a high referral rate [24,25,37], poor long-term outcomes with respect to coverage and referral rate [46].

Other factors that had an indirect impact on programme outcomes included the lack of dedicated screening personnel [23]; lack of professional resources/audiologists [73,80]; high ambient noise in the testing environment [30]; and the absence of diagnostic facilities [62]. A few studies mentioned challenges affecting programme implementation, such as the use of a three-step protocol only with OAE [60]; the difficulties of centralised programme implementation in remote locations [73] and delay in diagnosis in remote locations due to referral to regional facilities [80].

In screening for older children, children's attention was regarded as a major challenge resulting in poor accuracy [91]. Other key factors influencing programme outcomes included inadequate internet connectivity [8,85]; poor follow-up due to social stigma.

Facilitators:

Use of appropriate tracking or data management systems, were reported to be helpful in minimising lost-to-follow-up [18,26,35,42,57]. Combining hearing screening with other screenings improved follow-up rates

[47,81]. Several studies highlighted strategies to minimise false referral rates, including: i) employing a conducive environment and trained individuals [25]; ii) adding AABR in the initial stage of screening protocol [41]; screening between 3 and 5 days of age [81]; and incorporating tympanometry into the screening protocol [33]. Financial assistance in the form of funding [37,39,57]; and centralised hearing screening facilities or grouping more centres [18,26] were strategies reported in studies to improve coverage rates. Multi-centre based or a centralised hearing screening program was reported to be resource efficient with respect to cost, infrastructure and professionals [18].

DISCUSSION

The primary purpose of this review was to describe the models of hearing screening programmes implemented in young children in various Asian LICs and MICs in the published scientific literature. The inclusion of countries was based on the World bank classification rather than culturally defined regions, this led to a heterogenous inclusion with central Asian and middle eastern countries as well. Out of 61 L&MICs in Asia, only 14 countries reported hearing screening programs that fit our inclusion criteria. In a recent systematic review, high quality literature with hearing screening programs was reported to be primarily in high income countries [98], yet, it is also likely that resources for research and publication is low and hence is also low on priority in the L&MICs context. Though studies from both LICs and MICs were included, our results shows that most of the studies reporting on hearing screening were from the MICs, and more specifically from UMICs.. This suggests greater adoption of EHDI measures in UMICs, possibly due to greater availability of resources in comparison to LMICs and LICs.

Our review gathered evidence on hearing screening programmes in general, including screening protocols, screening tests, pass/fail criteria, screening personnel, diagnostic tests, use of ICT, and programme validity and efficacy. The hearing screening tools and protocols utilised for newborns, infants, and older children were similar to those used in high-income countries [99]. Despite the fact that the majority of programmes used a two-stage OAE(DP/TE) and ABR screening as preferred screening tools across countries, there was no consistency in protocol stages or screening tests undertaken. This was consistent with Kanji et al. (2018)'s assessment of NHS protocols, which revealed non-uniformity in the protocols followed.

It was also noted that objective hearing screening was most commonly reported over subjective hearing screening for newborns and infants. Only one study [20] found good sensitivity and specificity for behavioural hearing assessment for neonates and infants using calibrated noise makers. The use of objective screening in LICs and MICs implies a preference for international best practices based on Western contexts and guidelines [2]. However, it is important to assess the sustainability and long term outcomes of these efforts. Subjective single stage PTA screening, on the other hand, was extensively used in various screening programmes for older children above the age of three. This is comparable to high-income countries where

1 PTA screening is mandatory for children over the age of three [100,101]. In contrast, the current review
2 found a few public initiatives [29,54,97] that used questionnaire methods and this implies that mass
3 screening was being done by low cost tools like questionnaires where resources were limited.
4

5
6 Audiologists were the most common screening personnel in newborn screening programmes across Asian
7 LICs and MICs. This is in contrast to HICs, where nurses mostly performed hearing screening [102]. While
8 the majority of NHS programmes in Asian LICs and MICs were started by audiologists or otolaryngologists
9 in private hospitals, in most HICs the screening programmes were generally universal and followed as a part
10 of other normal newborns screening before discharge. Screening of older children was mostly done by
11 otolaryngologists, school instructors, and nurses. This could be because many of the screening programmes
12 for older children were conducted in schools or community settings in the absence of audiologists on-site. In
13 contrast, hearing screenings are carried out at child health clinics by a dedicated school nurse/audiologist in
14 high income countries [102].
15
16
17
18
19
20
21

22 Use of the test battery was limited in diagnostic confirmation of hearing loss. Detailed ABR testing was
23 considered as the standard diagnostic tool in many countries as it examines the entire peripheral auditory
24 pathway responsible for hearing. Apart from this, studies from China employed a test battery containing a
25 variety of tests altogether (eg. ASSR, ABR, and tympanometry) to confirm hearing loss. In WHO guidelines
26 for hearing screening, diagnostic test battery including ABR/ASSR, tympanometry, acoustic reflex,
27 otoscopic examination and medical evaluation was suggested [103]. Therefore, in HICs the diagnostic test
28 battery approach is mostly preferred [102]. In screening programmes for older children, medical (ENT)
29 examination in cases of conductive pathology and routine PTA with or without tympanometry were
30 prioritised as tests to confirm hearing loss. This is inconsistent with the WHO guidelines [103] and with the
31 programs from high income countries [102] It is important to note that PTA is a crucial test to differentiate
32 CDHL and SNHL. However information on bone conduction testing was limited.
33
34
35
36
37
38
39
40
41

42 Few studies reported the use of ICT to screen, manage data or perform diagnostic tests [8,85]. Lack of
43 utilization of ICT could be due to lack of adequate infrastructure, skills to support use of such tools. Yet, this
44 is not unique to LICs and MICs as evidence on use of ICT is limited even among high income countries
45 [98,99,102,104].
46
47
48

49 We assessed the validity and efficacy of the screening programme for infants and older children using a
50 purposively developed tool. None of the programmes reported met all of the criteria. The majority of
51 programmes made use of validated screening and diagnostic tools and reported the rate of hearing loss
52 identification. However, information on economic analysis was scarce, even though cost effectiveness is a
53 key variable for determining programme success [105]. Furthermore, studies predominantly only reported
54 identification but not intervention. The importance of EHDI programs is to intervene children so that the
55
56
57
58
59
60

1 pervasive impact of childhood hearing loss can be mitigated [106,107], therefore it is pertinent to know
2 whether such programmes resulted in early intervention.
3

4 Mean prevalence of hearing loss in newborns and infants was identified to be high in India (6/1000),
5 followed by Iran (3/1000) and China (2/1000). This is similar to the findings of Busse and colleagues (2021)
6 where the highest prevalence was found in India and Nigeria, followed by Iran. In another review,
7 prevalence was found to be highest in Asian countries compared to other regions [104]. A world report on
8 hearing (WHO, 2021) also stated that prevalence of congenital hearing loss in LICs and MICs is high
9 compared to HICs.
10
11
12
13
14

15 Barriers identified from our review were similar to those previously identified and discussed in various
16 studies including LICs and MICs [102,106,107,109]. However, a recent study in HICs found that when
17 hearing screening programmes were integrated as part of national screening with a dedicated screening
18 person, database management system, and appropriate guidelines, they were more successful. Therefore,
19 EHDI in LICs and MICs is also likely to be more successful when implemented through the government.
20
21
22
23
24

25 There were some limitations to the review which must be considered. No article was excluded based on
26 quality assessment owing to the limited literature available from L&MICs, yet the risk of bias in many
27 included studies was moderate to high. Furthermore, due to heterogeneity in the information obtained across
28 studies, no meta-analysis was performed. The generalisability of the findings was limited to Asian L&MICs.
29 Further, there were potential for publication bias as not all programmes would have published their results.
30 The coverage of EHDI in these countries was not assessed.
31
32
33
34

35 From this study, it is evident that strategies for EHDI in Asian L&MICs were similar to those recommended
36 in HICs. However, there is inadequate evidence related to the intended outcome of early intervention in this
37 context. Therefore, program planners and researchers must focus on impact evaluations that demonstrate the
38 long term viability of EHDI programs in the L&MICs context.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

FIGURES

Figure 1: PRISMA flowchart representing the selection of article at each stage

Figure 2: a) Validity and efficacy of screening programs for newborns and infants; b) Validity and efficacy of screening programs for older children

Figure 3: a) Forest plot of prevalence of hearing loss in newborns and infants in India; b) Forest plot of prevalence of hearing loss in newborns and infants in China ; c) Forest plot of prevalence of hearing loss in newborns and infants in Turkey; d) Forest plot of prevalence of hearing loss in newborns and infants in Iran; e) Forest plot of prevalence of hearing loss in newborns and infants in other Asian countries (Thailand, Malaysia, Nepal)

Conflict of interest: There is no conflict of interest associated with this study.

Funding statement: This review received in-part support from DBT/Wellcome Trust India Alliance (IA/CPHI/19/1/504614)

REFERENCES

1. World Health Organization (WHO). Deafness and Hearing Loss. 2021.
2. Busa J, Harrison J, Chappell J, *et al*. Year 2007 position statement: Principles and guidelines for early hearing detection and intervention programs. *Pediatrics* 2007;**120**:898–921.
3. Krishnan LA, Donaldson LK. Newborn Hearing Screening in Developing Countries: Understanding the Challenges and Complexities of Implementation. *Perspectives on Global Issues in Communication Sciences and Related Disorders* 2013;**3**:54.
4. Kanji A, Khoza-Shangase K. In pursuit of successful hearing screening: An exploration of factors associated with follow-up return rate in a risk-based newborn hearing screening programme. *Iran J Pediatr* 2018;**28**.
5. Louw B, Swanepoel DW. Infant hearing screening at immunization clinics in South Africa. *Int J Pediatr Otorhinolaryngol* 2006;**70**:1241–9.
6. de Kock T, Swanepoel DW, Hall JW. Newborn hearing screening at a community-based obstetric unit: Screening and diagnostic outcomes. *Int J Pediatr Otorhinolaryngol* 2016;**84**:124–31.
7. Friderichs N, Swanepoel D, 3rd HJW. Efficacy of a community-based infant hearing screening program utilizing existing clinic personnel in Western Cape, South Africa. *Int J Pediatr Otorhinolaryngol* 2012;**76**:552–9.
8. Piłka A, Skarżynska MB, Włodarczyk AW, *et al*. A Hearing Screening Program for Children in Primary Schools in Tajikistan : A Telemedicine Model. 2016;:2424–30.
9. Monica SD, Ramkumar V, Krumm M, *et al*. School entry level tele-hearing screening in a town in South India – Lessons learnt. *Int J Pediatr Otorhinolaryngol* 2017;**92**:130–5.
10. Dharmar M, Simon A, Sadorra C, *et al*. Reducing Loss to Follow-Up with Tele-audiology Diagnostic Evaluations. *Telemedicine and e-Health* 2016;**22**:1–6.
11. Yousuf Hussein S, Swanepoel DW, Mahomed F, *et al*. Community-based hearing screening for young children using an mHealth service-delivery model. *Glob Health Action* 2018;**11**.
12. 2Dsearch. <https://www.2dsearch.com/> (accessed 8 Oct 2022).
13. Ouzzani M, Hammady H, Fedorowicz Z, *et al*. Rayyan-a web and mobile app for systematic reviews. *Syst Rev* 2016;**5**:1–10.
14. Page MJ, McKenzie JE, Bossuyt PM, *et al*. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *The BMJ* 2021;**372**.
15. Critical Appraisal Tools | JBI. <https://jbi.global/critical-appraisal-tools> (accessed 8 Oct 2022).
16. Campbell M, McKenzie JE, Sowden A, *et al*. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. *BMJ* 2020;**20**:16890.
17. Biswas AK, Goswami SC, Baruah DK, *et al*. The Potential Risk Factors and the Identification of Hearing Loss in Infants. *Indian Journal of Otolaryngology and Head and Neck Surgery* 2012;**64**:214–7.

- 18 AK P. Early identification of hearing loss and centralized newborn hearing screening facility-the Cochin experience. *Indian Pediatr* 2011;**48**:355–9.
- 19 Mishra G, Sharma Y, Mehta K, *et al.* Efficacy of Distortion Product Oto-Acoustic Emission (OAE)/Auditory Brainstem Evoked Response (ABR) Protocols in Universal Neonatal Hearing Screening and Detecting Hearing Loss in Children <2 Years of Age. *Indian Journal of Otolaryngology and Head and Neck Surgery* 2013;**65**:105–10.
- 20 Ramesh A, Jagdish C, Nagapoorinima M, *et al.* Low cost calibrated mechanical noisemaker for hearing screening of neonates in resource constrained settings. *Indian J Med Res.* 2012;**135**:170–6.
- 21 Rai N, Thakur N. Universal screening of newborns to detect hearing impairment-Is it necessary? *Int J Pediatr Otorhinolaryngol* 2013;**77**:1036–41.
- 22 Kumar A, Shah N, Patel KB, *et al.* Hearing screening in a tertiary care hospital in India. *Journal of Clinical and Diagnostic Research* 2015;**9**:MC01–4.
- 23 Gupta S, Sah S, Som T, *et al.* Challenges of Implementing Universal Newborn Hearing Screening at a Tertiary Care Centre from India. *Indian J Pediatr* 2015;**82**:688–93.
- 24 Vignesh SS, Jaya V, Sasireka BI, *et al.* Prevalence and referral rates in neonatal hearing screening program using two step hearing screening protocol in Chennai - A prospective study. *Int J Pediatr Otorhinolaryngol* 2015;**79**:1745–7.
- 25 Vishwakarma C, Mathur R, Vishwakarma R, *et al.* Universal hearing screening vs targetted hearing screening: Make a choice. *Indian Journal of Otology* 2015;**21**:179–82.
- 26 Paul AK. Centralized Newborn Hearing Screening in Ernakulam, Kerala , Experience Over a Decade. *Indian Pediatr* 2016;**53**:15–7.
- 27 Sharma Y, Bhatt SH, Nimbalkar S, *et al.* Non-compliance With Neonatal Hearing Screening Follow-up in Rural Western India. *Indian Pediatr* 2018;**55**:482–4.
- 28 Kumar P, Adhisivam B, Vishnu Bhat B, *et al.* Screening for hearing loss among high risk neonates– Experience from a tertiary care center. *Current Pediatric Research* 2016;**20**:43–6.
- 29 Sachdeva K, Sao T. Outcomes of Newborn Hearing Screening Program: A Hospital Based Study. *Indian Journal of Otolaryngology and Head and Neck Surgery* 2017;**69**:194–8.
- 30 Kumar A, Gupta SC, Sinha VR. Universal Hearing Screening in Newborns Using Otoacoustic Emissions and Brainstem Evoked Response in Eastern Uttar Pradesh. *Indian Journal of Otolaryngology and Head and Neck Surgery* 2017;**69**:296–9.
- 31 Swain SK, Das A, Sahu MC, *et al.* Neonatal hearing screening: Our experiences at a tertiary care teaching hospital of eastern India. *Pediatr Pol* 2017;**92**:711–5.
- 32 Bhat J, Kurmi R, Kumar S, *et al.* Targeted screening for hearing impairment in neonates: A prospective observational study. *Indian Journal of Otology* 2018;**24**:42–6.
- 33 Bishnoi R, Baghel S, Agarwal S, *et al.* Newborn Hearing Screening: Time to Act! *Indian Journal of Otolaryngology and Head and Neck Surgery* 2019;**71**:1296–9.
- 34 Parab SR, Khan MM, Kulkarni S, *et al.* Neonatal Screening for Prevalence of Hearing Impairment in Rural Areas. *Indian Journal of Otolaryngology and Head and Neck Surgery* 2018;**70**:380–6.


- 1 35 Jacob J, Kurien M, Sindhusa, *et al.* Challenges of Universal Newborn Hearing Screening in a
2 Developing Country-a Double-Edged Sword. *Indian Journal of Otolaryngology and Head and Neck*
3 *Surgery* 2020;1-7.
- 4 36 Nishad A, Gangadhara Somayaji KS, Mithun HK, *et al.* A study of incidence of hearing loss in
5 newborn, designing a protocol and methodology to detect the same in a tertiary health-care center.
6 *Indian Journal of Otology* 2020;26:85–8.
- 7 37 Sija S, Gireesan VK, Kumar A, *et al.* Outcome of a Newborn Hearing Screening Program in a
8 Tertiary Care Center , South India. *The Journal of Early Hearing Detection and Intervention*
9 2022;7:101–7.
- 10 38 Zhang Z, Ding W, Liu X, *et al.* Auditory screening concurrent deafness predisposing genes screening
11 in 10,043 neonates in Gansu province, China. *Int J Pediatr Otorhinolaryngol* 2012;76:984–8.
- 12 39 Tobe RG, Mori R, Huang L, *et al.* Cost-Effectiveness Analysis of a National Neonatal Hearing
13 Screening Program in China: Conditions for the Scale-Up. *PLoS One* 2013;8.
- 14 40 Chen G, Yi X, Chen P, *et al.* A large-scale newborn hearing screening in rural areas in China. *Int J*
15 *Pediatr Otorhinolaryngol* 2012;76:1771–4.
- 16 41 Shang Y, Hao W, Gao Z, *et al.* An effective compromise between cost and referral rate: A sequential
17 hearing screening protocol using TEOAEs and AABRs for healthy newborns. *Int J Pediatr*
18 *Otorhinolaryngol* 2016;91:141–5.
- 19 42 Wenjin W, Xiangrong T, Yun L, *et al.* Neonatal hearing screening in remote areas of China: a
20 comparison between rural and urban populations. *J Int Med Res.* 2018;46:637–51.
- 21 43 Wang Q, Xiang J, Sun J, *et al.* Nationwide population genetic screening improves outcomes of
22 newborn screening for hearing loss in China. *Genetics in Medicine* 2019;21:2231–8.
- 23 44 Dai P, LH H, GJ W, *et al.* Concurrent Hearing and Genetic Screening of 180,469 Neonates with
24 Follow-up in Beijing, China. *Am J Hum Genet* 2019;105:803–12.
- 25 45 Zeng X, Liu Z, Wang J, *et al.* Combined hearing screening and genetic screening of deafness among
26 Hakka newborns in China. *Int J Pediatr Otorhinolaryngol* 2020;136.
- 27 46 Wen C, Li X, Huang L, *et al.* Current status of universal newborn hearing screening program at 26
28 institutions in China. *Int J Pediatr Otorhinolaryngol* 2020;138.
- 29 47 Guo L, Xiang J, Sun L, *et al.* Concurrent hearing and genetic screening in a general newborn
30 population. *Hum Genet.* 2020;139:521–30.
- 31 48 Guomei C, Luyan Z, Lingling D, *et al.* Concurrent Hearing and Genetic Screening among Newborns
32 in Ningbo, China. *Comput Math Methods Med* 2022;2022.
- 33 49 Ahmad A, Mohamad I, Mansor S, *et al.* Outcome of a newborn hearing screening program in a
34 tertiary hospital in Malaysia: the first five years. *Ann Saudi Med* 2011;31:24–8.
- 35 50 Wong Y, Mazlan R, ... NAW-J of M, *et al.* Quality measures of a multicentre universal newborn
36 hearing screening program in Malaysia. *Journal of medical screening*, 28; 3:238-243.
- 37 51 Tungvachirakul V, Boonmee S, Nualmoosik T, *et al.* Newborn hearing screening at Rajavithi
38 Hospital, Thailand: hearing loss in infants not admitting in intensive care unit. *J Med Assoc Thai*
39 2011;94 Suppl 2.
- 40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 52 Poonual W, Navacharoen N, Kangsanarak J, *et al.* Risk factors for hearing loss in infants under universal hearing screening program in Northern Thailand. *J Multidiscip Healthc* 2016;**9**:1–5.
- 53 Poonual W, Navacharoen N, Kangsanarak J, *et al.* Outcome of early identification and intervention on infants with hearing loss under universal hearing screening program. *Journal of the Medical Association of Thailand* 2017;**100**:197–206.
- 54 Poonual W, Navacharoen N, Kangsanarak J, *et al.* Hearing loss screening tool (COBRA score) for newborns in primary care setting. *Korean J Pediatr* 2017;**60**:353–8.
- 55 Pitathawatchai P, Khaimook W, Kirtsreesakul V. Pilot implementation of newborn hearing screening programme at four hospitals in southern Thailand. *Bull World Health Organ* 2019;**97**:663–71.
- 56 Ray P, Thakali S, Prajapati S. Newborn Hearing Screening: Experience from a Tertiary level Hospital in Nepal. *Nepal Medical Journal* 2021;**4**:33–6.
- 57 Mazlan R, Raman K, Abdullah A. A 10 - year retrospective analysis of newborn hearing screening in a tertiary hospital in Malaysia. *The Egyptian Journal of Otolaryngology* 2022;**38**.
- 58 Shameem M, Saha KL, Uddin MB, *et al.* Hearing Screening to Evaluate the Status of Newborn Hearing Impairment in the NICU of a Tertiary Hospital. *TAJ: Journal of Teachers Association* 2022;**35**:77–82.
- 59 Khaimook W, Suwanno R, Dindamrongkul R, *et al.* An Early Hearing Detection and Intervention Program in Songklanagarind Hospital. *Journal of Health Science and Medical Research* 2022;**40**:551–9.
- 60 Tasci Y, Muderris II, Erkaya S, *et al.* Newborn hearing screening programme outcomes in a research hospital from Turkey. *Child Care Health Dev* 2010;**36**:317–22.
- 61 Sennaroglu G, Akmese PP. Risk factors for hearing loss and results of newborn hearing screening in rural area. *J Int Adv Otol* 2011;**7**:343.
- 62 Ulusoy S, Ugras H, Cingi C, *et al.* The results of national newborn hearing screening (NNHS) data of 11,575 newborns from west part of Turkey. *Eur Rev Med Pharmacol Sci* 2014;**18**:2995–3003.
- 63 Kemaloğlu Y, Gökdoğan Ç, ... BG-EA of, *et al.* Newborn hearing screening outcomes during the first decade of the program in a reference hospital from Turkey. *European Archives of Oto-Rhino-Laryngology* 2016; **273**: 1143-1149.
- 64 Yorulmaz A, Genç U, Yılmaz FH, *et al.* Evaluation and importance of our newborn hearing screening results. *Haseki Tip Bulteni* 2017;**55**:111–8.
- 65 Çelik O, Eskiizmir G, Uz U. A comparison of thresholds of auditory steady-state response and auditory brainstem response in healthy term babies. *Journal of International Advanced Otology* 2016;**12**:277–81.
- 66 Öztürk S, Aktaş S, ... LK-TA of, *et al.* The follow-up results of newborn hearing screening of Gaziosmanpaşa Taksim Research and Training Hospital. *Turkish Archives of Pediatrics/Türk Pediatri Arşivi*, 2018; **53**: 1
- 67 Hamdi A. Evaluation of 1808 Newborns Hearing Screening Outcome. *Eurasian J Med Oncol* Published Online First: 2018.
- 68 Yücel A, Alataş N, Yücel H, *et al.* Newborn hearing screening results of refugees living in our city and the factors affecting the results. *Int J Pediatr Otorhinolaryngol* 2019;**123**:187–90.

- 1 69 Arslan S, Işık AÜ, Imamoğlu M, *et al.* Universal newborn hearing screening; Automated transient
2 evoked otoacoustic emissions. *B-ENT* 2013;**9**:123–31.
- 3 70 Çıkırıkçı S, Deniz H, Gülşen S. Comparison of hearing screening results of Syrian refugees and
4 Turkish newborns. *Int J Pediatr Otorhinolaryngol* 2020;**135**.
- 5 71 Arjmandi F, Farhangfar B, Mehrabi S, *et al.* Prevalence of deafness and hearing screening in
6 newborns in Isfahan. *Journal of Research in Medical Sciences* 2012;**17**:S233–6.
- 7 72 Islami Z, Baradaranfar M-H, Mehrparvar A-H, *et al.* Frequency of hearing impairment among full-
8 term newborns in Yazd, Iran. *Iran J Pediatr* 2013;**23**:349–52.
- 9 73 Firoozbakht M, Mahmoudian S, Alaeddini F, *et al.* Community-based newborn hearing screening
10 programme for early detection of permanent hearing loss in Iran: An eight-year cross-sectional study
11 from 2005 to 2012. *J Med Screen* 2014;**21**:10–7.
- 12 74 Zahed Y, Zamani ; Mohammad, Hashemi A, *et al.* Screening of Hearing in Newborn Infants: Follow-
13 Up and Outcome After 40 930 Births in Babol, Northern Iran. 2018.
- 14 75 Farhat AS, Ghasemi MM, Akhondian J, *et al.* Assessment of the prevalence of hearing impairment in
15 neonates born in Imam Reza, Ghaem and OM-Albanin Hospitals of Mashhad. *Iranian Journal of*
16 *Neonatology* 2014;**5**:17–20.
- 17 76 Haghshenas M, Fard H, Delavari K, *et al.* Auditory screening in infants for early detection of
18 permanent hearing loss in northern Iran. *Ann Med Health Sci Res* 2014;**4**:340.
- 19 77 Baradaranfar MH, Mehrparvar AH, Mostaghaci M, *et al.* Hearing abnormality in Neonate Intensive
20 Care Unit (NICU), Yazd-Iran. *Int J Pediatr* 2014;**2**:113–7.
- 21 78 Azizi A, Amirian F, Dargahi A, *et al.* Evaluation of universal newborn hearing screening with
22 TEOAE and ABR: A cross-sectional study with the literature review. *International Journal of*
23 *Tropical Medicine* 2016;**11**:84–9.
- 24 79 Tajik S, Ahmadpour-Kacho M. Early diagnosis and intervention for hearing loss in newborns
25 discharged from intensive care units: A four-year follow-up study in North of Iran. *Int J Pediatr*
26 2016;**4**:3283–91.
- 27 80 Saki N, Bayat A, Hoesinabadi R, *et al.* Universal newborn hearing screening in southwestern Iran. *Int*
28 *J Pediatr Otorhinolaryngol* 2017;**97**:89–92.
- 29 81 Rahimi V, Mohammadkhani G, Javadi F. Improving universal newborn hearing screening outcomes
30 by conducting it with thyroid screening. *Int J Pediatr Otorhinolaryngol* 2018;**111**:111–4.
- 31 82 Tuli IP, Pal I, Sengupta S, *et al.* Role of early audiological screening and intervention. *Indian Journal*
32 *of Otology* 2012;**18**:148–53.
- 33 83 Chadha SK, Sayal A, Malhotra V, *et al.* Prevalence of preventable ear disorders in over 15 000
34 schoolchildren in northern India. *Journal of Laryngology and Otology* 2013;**127**:28–32.
- 35 84 Ramkumar V, John KR, Selvakumar K, *et al.* Cost and outcome of a community-based paediatric
36 hearing screening programme in rural India with application of tele-audiology for follow-up
37 diagnostic hearing assessment. *Int J Audiol* 2018;**57**:407–14.
- 38 85 Ramkumar V, Nagarajan R, Shankarnarayan VC, *et al.* Implementation and evaluation of a rural
39 community-based pediatric hearing screening program integrating in-person and tele-diagnostic
40 auditory brainstem response (ABR). *BMC Health Serv Res* 2019;**19**.

- 86 Verma PK, Chopra D, Khwaja M, *et al.* Prevalence of Hearing Impairment in School Children in A Rural area of Lucknow- A Cross Sectional Study. *International Journal of Pharmaceutical and Clinical Research* 2022;**14**:80–4.
- 87 Shekhar H, Khokhar A, Motwani G, *et al.* Prevalence of ear morbidities among school children in Delhi, India: a cross-sectional study. *Int J Adolesc Med Health* Published Online First: 2020.
- 88 Lü J, Huang Z, Yang T, *et al.* Screening for delayed-onset hearing loss in preschool children who previously passed the newborn hearing screening. *Int J Pediatr Otorhinolaryngol* 2011;**75**:1045–9.
- 89 Chen G, Fu S, Luo S, *et al.* Screening of delayed-onset hearing loss in preschool children in the mid-south of China. *Int J Audiol* 2013;**52**:568–71.
- 90 Wu W, Lü J, Li Y, *et al.* A new hearing screening system for preschool children. *Int J Pediatr Otorhinolaryngol* 2014;**78**:290–5.
- 91 Kam ACS, Li LKC, Yeung KNK, *et al.* Automated hearing screening for preschool children. *J Med Screen* 2014;**21**:71–5.
- 92 Tokgöz-Yılmaz S, Özcebe E, MD T, *et al.* Evaluation of hearing and speech-language in preschool children: how important, why we should perform? *Turk J Pediatr* 2013;**55**:606–11.
- 93 Kaplama ME, Ak S. The results of hearing screening in refugee school children living in Şanlıurfa /Turkey and the related risk factors. *Int J Pediatr Otorhinolaryngol* 2020;**134**.
- 94 TarvijEslami S, Nassirian H, Bayesh S. Impact on performance of hearing screening program through prevalence and diagnostic age evaluation in elementary school students in north-eastern city of Iran, Mashhad. *Pediatr Pol* 2017;**92**:705–10.
- 95 Jalali MM, Nezamdoost F, Ramezani H, *et al.* Prevalence of hearing loss among school-age children in the north of Iran. *Iran J Otorhinolaryngol* 2020;**32**:85–92.
- 96 Alaqrabawi WS, Alshawabka AZ, Al-Addasi ZM, *et al.* What are the predictive causes of conductive hearing loss in school-age children in Jordan? *Jordan Med J* 2016;**50**:187–94.
- 97 Al-Obeidy SH, Abdulrahman ZN, Zaradwy IAR. School-entry Screening Program for Ear and Hearing Problems in Tikrit, Iraq. *Middle East Journal of Family Medicine* 2019;**17**.
- 98 Yoshinaga-Itano C, Manchaiah V, Hunnicutt C. Outcomes of Universal Newborn Screening Programs: Systematic Review. *J Clin Med* 2021;**10**:2784.
- 99 Kanji A, Khoza-Shangase K, Moroe N. Newborn hearing screening protocols and their outcomes: A systematic review. *Int J Pediatr Otorhinolaryngol.* 2018;**115**:104–9.
- 100 Bright, K., Greeley, C.O., Eichwald, J., Loveland, C.O. and Tanner, G., American Academy of Audiology childhood hearing screening guidelines. Reston, VA: American Academy of Audiology Task Force. 2011.
- 101 Childhood Hearing Screening. <https://www.asha.org/practice-portal/professional-issues/childhood-hearing-screening/> (accessed 7 Oct 2022).
- 102 Bussé AML, Mackey AR, Carr G, *et al.* Assessment of hearing screening programmes across 47 countries or regions III: provision of childhood hearing screening after the newborn period. *Int J Audiol* 2021;**60**:841–8.
- 103 World Health Organization. Hearing screening: considerations for implementation. World Health Organization. 2021.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- 104 Butcher E, Dezateux C, Cortina-Borja M, *et al.* Prevalence of permanent childhood hearing loss detected at the universal newborn hearing screen: Systematic review and metaanalysis. *PLoS One* 2019;**14**:1–21.
- 105 Colgan S, Gold L, Wirth K, *et al.* The cost-effectiveness of universal newborn screening for bilateral permanent congenital hearing impairment: Systematic review. *Acad Pediatr* 2012;**12**:171–80.
- 106 Neumann K, Chadha S, Tavartkiladze S *et al.* Newborn and infant hearing screening facing globally growing numbers of people suffering from disabling hearing loss. *International Journal of Neonatal Screening* 2019; **5**:1
- 107 Olusanya B. Screening for neonatal deafness in resource-poor countries: challenges and solutions. *Res Rep Neonatol* 2015;:51.
- 108 OM da S. World Report On Hearing. *World Health Organization* 2021;:1–272.
- 109 Galhotra A, Sahu P. Challenges and solutions in implementing hearing screening program in India. *Indian Journal of Community Medicine* 2019;**44**:299–302.



39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Mono Figure 1: PRISMA Flowchart representing selection of studies at different levels of screening

72x75mm (300 x 300 DPI)

| Citation | Country | Validity of the screening program | | | Efficacy of the screening program | | |
|---------------------------------|-----------|-----------------------------------|---|--|-----------------------------------|-----------------------------|---------------------------|
| | | Use of validated screening tools | Valid diagnostic being used within the scope of the program | Implementation phase of the program (years duration) | Program's economic analysis | Frequency of identification | Frequency of intervention |
| Sharma et al., 2012 | India | | | | | | |
| Paul et al., 2011 | India | | | | | | |
| Sharma et al., 2013 | India | | | | | | |
| Ramesh et al., 2012 | India | | | | | | |
| Rao & Tahir et al., 2013 | India | | | | | | |
| Kumar et al., 2015 | India | | | | | | |
| Agarwal et al., 2015 | India | | | | | | |
| Vignesh et al., 2015 | India | | | | | | |
| Vishwakarma et al., 2016 | India | | | | | | |
| Paul et al., 2016 | India | | | | | | |
| Kumar et al., 2016 | India | | | | | | |
| Bhat et al., 2018 | India | | | | | | |
| Sachdeva & Sas et al., 2017 | India | | | | | | |
| Kumar et al., 2017 | India | | | | | | |
| Devan et al., 2017 | India | | | | | | |
| Bhat et al., 2018 | India | | | | | | |
| Bhushan et al., 2018 | India | | | | | | |
| Parab et al., 2018 | India | | | | | | |
| Jacob et al., 2020 | India | | | | | | |
| Nehal et al., 2020 | India | | | | | | |
| Gopa et al., 2022 | India | | | | | | |
| Zhang et al., 2012 | China | | | | | | |
| Huang et al., 2012 | China | | | | | | |
| Chen et al., 2012 | China | | | | | | |
| Shang et al., 2018 | China | | | | | | |
| Wang et al., 2018 | China | | | | | | |
| Wang et al., 2019 | China | | | | | | |
| Dai et al., 2019 | China | | | | | | |
| Deng et al., 2020 | China | | | | | | |
| Wang et al., 2020 | China | | | | | | |
| Gao et al., 2020 | China | | | | | | |
| Gumert et al., 2022 | China | | | | | | |
| Ahmad et al., 2011 | Malaysia | | | | | | |
| Ming et al., 2020 | Malaysia | | | | | | |
| Muzni et al., 2022 | Malaysia | | | | | | |
| Farooq et al., 2019 | Turkey | | | | | | |
| Bennaroglu & Akmeso, 2011 | Turkey | | | | | | |
| Ustoy et al., 2014 | Turkey | | | | | | |
| Kormoglu et al., 2016 | Turkey | | | | | | |
| Yonmaz et al., 2017 | Turkey | | | | | | |
| Can et al., 2016 | Turkey | | | | | | |
| Orkun et al., 2017 | Turkey | | | | | | |
| Hanci, 2018 | Turkey | | | | | | |
| Vicini et al., 2019 | Turkey | | | | | | |
| Arslan et al., 2020 | Turkey | | | | | | |
| Cakirky et al., 2020 | Turkey | | | | | | |
| Ajzami et al., 2012 | Iran | | | | | | |
| Iran et al., 2013 | Iran | | | | | | |
| Firoozbakhsh et al., 2014 | Iran | | | | | | |
| Zahedi et al., 2014 | Iran | | | | | | |
| Farah et al., 2014 | Iran | | | | | | |
| Haghighian et al., 2014 | Iran | | | | | | |
| Baradaranfar et al., 2014 | Iran | | | | | | |
| Azizi et al., 2016 | Iran | | | | | | |
| Fajri & Ahmadi-pour-Kadko, 2015 | Iran | | | | | | |
| Saki et al., 2017 | Iran | | | | | | |
| Rahimi et al., 2018 | Iran | | | | | | |
| Thungsochirakul et al., 2011 | Thailand | | | | | | |
| Poonai et al., 2016 | Thailand | | | | | | |
| Poonai et al., 2017b | Thailand | | | | | | |
| Poonai et al., 2017c | Thailand | | | | | | |
| Pitthawattha et al., 2019 | Thailand | | | | | | |
| Ray et al., 2021 | Nepal | | | | | | |
| Shanmugan et al., 2022 | Sri Lanka | | | | | | |
| Chansook et al., 2022 | Thailand | | | | | | |

| Citation | Country | Validity of the screening program | | | Efficacy of the screening program | | |
|-------------------------|-----------|-----------------------------------|---|--|-----------------------------------|-----------------------------|---------------------------|
| | | Use of validated screening tools | Valid diagnostic being used within the scope of the program | Implementation phase of the program (years duration) | Program's economic analysis | Frequency of identification | Frequency of intervention |
| Tal et al., 2012 | India | | | | | | |
| Chanda et al., 2012 | India | | | | | | |
| Shekar et al., 2020 | India | | | | | | |
| Sharma et al., 2022 | India | | | | | | |
| Lu et al., 2011 | China | | | | | | |
| Chen et al., 2012 | China | | | | | | |
| Haghighian et al., 2013 | Iran | | | | | | |
| Napata et al., 2020 | Turkey | | | | | | |
| Shanmugan et al., 2022 | Sri Lanka | | | | | | |
| Isa et al., 2020 | Iran | | | | | | |
| Shanmugan et al., 2019 | Thailand | | | | | | |
| Shanmugan et al., 2016 | Thailand | | | | | | |
| Shanmugan et al., 2019 | Thailand | | | | | | |
| Shanmugan et al., 2013 | Thailand | | | | | | |
| Shanmugan et al., 2014 | Thailand | | | | | | |
| Shanmugan et al., 2018 | Thailand | | | | | | |
| Shanmugan et al., 2019 | Thailand | | | | | | |

Key: ■ Met criteria ■ Not met criteria

Figure 2: a) Validity and efficacy of screening programs for newborns and infants; b) Validity and efficacy of screening programs for older children

296x575mm (300 x 300 DPI)




Figure 3: a) Forest plot of prevalence of hearing loss in newborns and infants in India; b) Forest plot of prevalence of hearing loss in newborns and infants in China ; c) Forest plot of prevalence of hearing loss in newborns and infants in Turkey; d) Forest plot of prevalence of hearing loss in newborns and infants in Iran; e) Forest plot of prevalence of hearing loss in newborns and infants in other Asian countries (Thailand, Malaysia, Nepal)

89x194mm (300 x 300 DPI)

Supplementary table 1A: Quality appraisal for cross sectional studies using JBI tool for cross sectional studies

| Author and Year | Were the criteria for inclusion in the sample clearly defined? | Were the study subjects and the setting described in detail? | Was the exposure measured in a valid and reliable way? | Were objective, standard criteria used for measurement of the condition? | Were confounding factors identified? | Were strategies to deal with confounding factors stated? | Were the outcomes measured in a valid and reliable way? | Was appropriate statistical analysis used? |
|----------------------------|--|--|--|--|--------------------------------------|--|---|--|
| Biswas et al., 2012 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Paul et al.,2011 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Mishra et al., 2013 | Yes | Yes | NA | Yes | No | NA | Yes | No |
| Ramesh et al., 2012 | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes |
| Kumar et al.,2015 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Gupta et al.,2015 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Vignesh et al.,2015 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Vishwakarma et al.,2015 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Paul et al.,2016 | Yes | Yes | NA | Yes | No | NA | Yes | NA |
| Sharma et al., 2018 | No | Yes | NA | Yes | No | Na | Yes | Yes |
| Kumar et al.,2016* | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Sachdeva & Sao et al.,2017 | Yes | Yes | Yes | Yes | No | NA | Yes | Yes |
| Swain et al.,2017 | Yes | Yes | Yes | Yes | No | No | Yes | Yes |
| Bhat et al.,2018 | Yes | Yes | Yes | Yes | No | NA | Yes | Yes |
| Bishnoi et al.,2018 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |

| | | | | | | | | |
|----------------------------|-----|-----|-----|-----|----|----|-----|-----|
| Parab et al.,2018 * | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Jacob et al.,2020 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Nishad et al.,2020 | Yes | Yes | NA | Yes | No | No | Yes | Yes |
| Zhang et al., 2012 | Yes | Yes | NA | Yes | No | No | No | Yes |
| Tobe et al.,2013* | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Chen et al.,2012 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Shang et al.,2016 | Yes | Yes | NA | Yes | No | NA | Yes | YEs |
| Wenjin et al., 2018 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Dai et al.,2019 | Yes | YEs | NA | Yes | No | NA | Yes | Yes |
| Zeng et al., 2020 | Yes | Yes | Yes | Yes | NA | NA | Yes | Yes |
| Wen et al., 2020 * | Yes | Yes | NA | yes | No | NA | Yes | Yes |
| Guo et al., 2020 | Yes | Yes | Yes | Yes | No | NA | Yes | Yes |
| Guomei et al.,2022 | Yes | Yes | NA | Yes | No | NA | No | Yes |
| Ahmad et al.,2011 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Wong et al.,2020 | Yes | Yes | Yes | Yes | No | NA | Yes | Yes |
| Tungvachirakul et al.,2011 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Poonual et al.,2017 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Poonual et al., 2017b | Yes | Yes | Yes | Yes | No | NA | Yes | Yes |
| Pitathawatchai et al.,2019 | Yes | Yes | Yes | Yes | No | Na | Yes | Yes |
| Ray et al.,2021 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Mazlan et al.,2022 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |

| | | | | | | | | |
|-------------------------------|-----|-----|-----|-----|----|----|-----|-----|
| Shameem et al., 2022 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Khaimook et al.,2022 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Sennaroglu & Akmese, 2011 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Ulusoy et al.,2014 | yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Kemaloğlu et al., 2016 | Yes | Yes | NA | Yes | No | No | Yes | Yes |
| Yorulmaz et al., 2017 | Yes | Yes | Yes | Yes | No | NA | Yes | Yes |
| Ozturk et al.,2017 | Yes | Yes | NA | Yes | No | No | Yes | Yes |
| Hamdi, 2018 | Yes | Yes | NA | Yes | No | No | Yes | Yes |
| Yücel et al., 2019 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Arslan et al., 2013 | Yes | Yes | Yes | Yes | No | NA | Yes | Yes |
| Çıkrıkçı et al., 2020* | Yes | Yes | Yes | Yes | No | NA | Yes | Yes |
| Arjmandi et al., 2012 | Yes | Yes | No | Yes | No | NA | Yes | Yes |
| Islami et al.,2013 | Yes | Yes | Yes | Yes | No | NA | Yes | Yes |
| Firoozbakht et al.,2014 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Zahed et al., 2014* | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Farhat et al., 2014 | Yes | Yes | No | Yes | No | NA | Yes | Yes |
| Haghshenas et al., 2014 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Baradaranfar et al., 2014 | Yes | Yes | Yes | Yes | No | NA | Yes | Yes |
| Azizi et al., 2016 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Tajik & Ahmadpour-Kacho, 2016 | Yes | Yes | NA | Yes | No | NA | Yes | YEs |
| Saki et al.,2017 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |

| | | | | | | | | |
|---------------------------|-----|-----|-----|-----|-----|-----|-----|-----|
| Tuli et al.,2012 | Yes | Yes | No | Yes | Yes | No | Yes | Yes |
| Chadha et al., 2013 | Yes | Yes | NA | No | Yes | Yes | Yes | Yes |
| Ramkumar et al.,2018 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Ramkumar et al.,2019 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Verma et al.,2022 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Shekhar et al., 2020 | Yes | Yes | Yes | Yes | Yes | No | Yes | Yes |
| Lu et al.,2011 | Yes | Yes | Yes | Yes | No | No | Yes | Yes |
| Chen et al.,2013 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Wu et al.,2014 | Yes | Yes | NA | No | No | NA | Yes | Yes |
| Kam et al.,2014 | Yes | YEs | NA | Yes | NA | NA | YES | YES |
| Tokgöz-Yılmaz et al.,2013 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Kaplama et al.,2020 | Yes | Yes | Yes | Yes | No | NA | Yes | Yes |
| TarviEslami et al.,2017 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Jalali et al.,2020 | Yes | Yes | Yes | No | No | NA | Yes | Yes |
| Pilka et al.,2016 | No | Yes | NA | Yes | No | NA | Yes | Yes |
| Alaqrabawi et al.,2016 | Yes | Yes | NA | Yes | No | NA | Yes | Yes |
| Al-Obeidy et al.,2019 | No | Yes | NA | No | No | NA | Yes | Yes |

Supplementary table 1B: Quality appraisal for cohort studies using JBI tool for cohort study

| Author & year | Were the two groups similar and recruited from the same population? | Were the exposures measured similarly to assign people to both exposed and unexposed groups? | Was the exposure measured in a valid and reliable way? | Were confounding factors identified? | Were strategies to deal with confounding factors stated? | Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? | Were the outcomes measured in a valid and reliable way? | Was the follow up time reported and sufficient to be long enough for outcomes to occur? | Was follow up complete, and if not, were the reasons to loss to follow up described and explored? | Were strategies to address incomplete follow up utilized? | Was appropriate statistical analysis used? |
|---------------------|---|--|--|--------------------------------------|--|--|---|---|---|---|--|
| Poonual et al.,2016 | Yes | Yes | Yes | No | NA | Yes | Yes | Yes | Yes | No | Yes |
| Sija et al.,2022 | Yes | Yes | NA | No | NA | Yes | Yes | Yes | Yes | No | Yes |
| Rahimi et al.,2018 | Yes | Yes | Yes | No | NA | Yes | Yes | Yes | No | No | Yes |
| Celik et al.,2016 | Yes | Yes | Yes | No | No | Yes | Yes | Yes | Yes | Yes | Yes |
| Tasci et al.,2010 | Yes | Yes | Yes | No | NA | Yes | Yes | Yes | Yes | Yes | Yes |
| Wang et al., 2019 | Yes | Yes | Yes | No | NA | Yes | yes | Yes | Yes | Yes | Yes |
| Kumar et al.,2017 | Yes | Yes | Yes | No | NA | Yes | Yes | Yes | Yes | Yes | Yes |
| Rai & Thakur 2013 | Yes | Yes | Yes | No | NA | Yes | Yes | Yes | Yes | Yes | Yes |